STOCK TITAN

MaxCyte to acquire Akron Bio for about $152M

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
10-Q

Rhea-AI Filing Summary

MaxCyte, Inc. reported third-quarter revenue of $10.152 million, up 49% from $6.829 million a year earlier, and a net loss of $4.762 million versus $12.416 million. SPL milestone and royalty revenue contributed to the quarterly increase. For the nine months ended September 30, 2026, total revenue was $27.074 million versus $25.726 million, while core revenue declined 9% to $20.877 million from $22.848 million.

On November 9, 2026, MaxCyte entered a definitive agreement to acquire Akron Bio for approximately $151.8 million: $105 million in cash at closing, subject to customary adjustments; 20,639,733 common shares valued at approximately $26.8 million based on the November 9, 2026 stock price; and $20.0 million in guaranteed deferred payments, with $10.0 million due in January 2028 and $10.0 million in January 2029. Closing is expected before the end of 2026, subject to customary conditions.

MaxCyte also entered a commitment letter for a credit facility of up to $75.0 million. It expects to draw $20.0 million from the term loan and $2.0 million from the revolver at acquisition closing; the facility is subject to definitive loan documentation and other conditions, including that closing.

4 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 1 point

How the balance works

Positive

  • Moderate pointThird-quarter revenue rose 49% to $10.152 million from $6.829 million.
  • Moderate pointThird-quarter net loss decreased to $4.762 million from $12.416 million.
  • Moderate pointNine-month operating cash used declined to $18.336 million from $31.721 million.
  • Moderate pointNine-month total revenue increased 5% to $27.074 million.

Negative

  • Moderate pointNine-month core revenue declined 9% to $20.877 million.

Filing Explained

The acquisition-linked financing would add senior secured, SOFR-linked debt only if borrowed, with principal and accrued interest due five years after acquisition closing.

MaxCyte’s agreement to acquire Akron Bio remains subject to customary closing conditions; if completed, the agreed issuance of 20,639,733 common shares would increase the share count and reduce existing holders’ percentage ownership.

If borrowed, the facility’s term loan and revolver are senior secured, with interest tied to SOFR: $5.25% above SOFR for the term loan, subject to a 2.00% floor, and $3.75% above SOFR for the revolver, subject to a 2% floor. Both loans mature five years after the acquisition closes, when outstanding principal and accrued interest are due.

Third-quarter revenue $10.152 million Three months ended September 30, 2026; $6.829 million in the same period of 2025
Third-quarter net loss $4.762 million Three months ended September 30, 2026; $12.416 million in the same period of 2025
Nine-month total revenue $27.074 million Nine months ended September 30, 2026; $25.726 million in 2025
Nine-month core revenue $20.877 million Nine months ended September 30, 2026; $22.848 million in 2025
Net cash used in operating activities $18.336 million Nine months ended September 30, 2026; $31.721 million in 2025
Akron Bio acquisition consideration Approximately $151.8 million Definitive agreement entered November 9, 2026
Common shares in acquisition consideration 20,639,733 shares Shares valued at approximately $26.8 million based on MaxCyte’s stock price as of November 9, 2026
Credit facility Up to $75.0 million Commitment letter entered November 9, 2026; subject to definitive loan documentation and other conditions
Strategic Platform License financial
"28 Strategic Platform License (“SPL”) partners"
A strategic platform license is a contractual agreement that lets one company use another’s core technology or ‘toolkit’ across multiple products or programs, often with exclusivity, milestone payments and ongoing royalties. Investors care because it can create durable, scalable revenue streams, spread development costs and risks across many future products, and signal a long-term partnership that may accelerate product launches and market reach.
SOFR floor financial
"subject to a SOFR floor of 2.00%"
asset-based revolving credit facility financial
"senior secured asset-based revolving credit facility"
A loan arrangement where a lender agrees to make funds available up to a set limit that a borrower can draw, repay, and draw again, with the amount available tied to the value of specific assets (like inventory, receivables, or equipment) pledged as collateral. It matters to investors because it provides flexible working capital while limiting risk exposure: the company can fund growth or cover shortfalls quickly, but borrowing capacity can shrink if asset values fall.
deferred revenue financial
"Deferred revenue represents payments received for performance obligations not yet satisfied"
Cash a company has already received for goods or services it has promised but not yet delivered; it's recorded as a liability because the company still owes that product, service, or future revenue recognition. For investors, deferred revenue signals upcoming work or deliveries that will convert into reported sales over time and affects short-term obligations, cash flow quality, and how quickly a firm can grow recognized revenue—think of it like prepaid subscriptions or gift cards a business must honor later.
anti-dilutive financial
"the impact of all dilutive potential common shares is anti-dilutive"
A claim, security feature, or action described as anti-dilutive prevents or does not cause a reduction in existing shareholders’ per-share values when additional shares could be issued. For example, certain convertible securities or corporate actions are treated as anti-dilutive for earnings-per-share calculations if including them would raise EPS rather than lower it; investors watch this because it affects reported per-share metrics, ownership percentages, and valuation comparisons, like keeping pie slices the same size instead of making them smaller.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much is MXCT acquiring Akron Bio for?

MaxCyte agreed to acquire Akron Bio for approximately $151.8 million. Consideration includes $105 million in cash at closing, subject to customary adjustments; 20,639,733 common shares valued at approximately $26.8 million based on the November 9, 2026 stock price; and $20.0 million in guaranteed deferred payments, with $10.0 million due in January 2028 and $10.0 million due in January 2029.

What were MXCT’s third-quarter 2026 revenue and net loss?

Revenue was $10.152 million, compared with $6.829 million in the third quarter of 2025; net loss was $4.762 million compared with $12.416 million.

When is MXCT’s Akron Bio acquisition expected to close?

MaxCyte expects the acquisition to close before the end of 2026, subject to customary closing conditions. It stated there can be no assurance the acquisition will close on that timeline or at all.

What are the interest rates on MXCT’s proposed financing?

The Term Loan bears interest at 30-day forward-looking SOFR plus 5.25%, subject to a 2.00% SOFR floor. The Revolver bears interest at SOFR plus 3.75%, subject to a 2% SOFR floor and availability conditions. Both mature five years after the acquisition closes.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
P0Y0001287098--12-312026Q3falseP7YP1Yhttp://fasb.org/us-gaap/2026#SecuredOvernightFinancingRateSofrMember0001287098us-gaap:TreasuryStockCommonMember2026-07-012026-09-300001287098us-gaap:TreasuryStockCommonMember2026-04-012026-06-3000012870982026-05-012026-05-310001287098us-gaap:CommonStockMember2026-07-012026-09-300001287098us-gaap:CommonStockMember2026-01-012026-03-310001287098us-gaap:CommonStockMember2025-07-012025-09-300001287098us-gaap:CommonStockMember2025-01-012025-03-310001287098us-gaap:CommonStockMember2026-04-012026-06-300001287098us-gaap:CommonStockMember2025-04-012025-06-300001287098us-gaap:TreasuryStockCommonMember2026-09-300001287098us-gaap:RetainedEarningsMember2026-09-300001287098us-gaap:AdditionalPaidInCapitalMember2026-09-300001287098us-gaap:TreasuryStockCommonMember2026-06-300001287098us-gaap:RetainedEarningsMember2026-06-300001287098us-gaap:AdditionalPaidInCapitalMember2026-06-3000012870982026-06-300001287098us-gaap:RetainedEarningsMember2026-03-310001287098us-gaap:AdditionalPaidInCapitalMember2026-03-3100012870982026-03-310001287098us-gaap:RetainedEarningsMember2025-12-310001287098us-gaap:AdditionalPaidInCapitalMember2025-12-310001287098us-gaap:RetainedEarningsMember2025-09-300001287098us-gaap:AdditionalPaidInCapitalMember2025-09-300001287098us-gaap:RetainedEarningsMember2025-06-300001287098us-gaap:AdditionalPaidInCapitalMember2025-06-3000012870982025-06-300001287098us-gaap:RetainedEarningsMember2025-03-310001287098us-gaap:AdditionalPaidInCapitalMember2025-03-3100012870982025-03-310001287098us-gaap:RetainedEarningsMember2024-12-310001287098us-gaap:AdditionalPaidInCapitalMember2024-12-310001287098us-gaap:CommonStockMember2026-09-300001287098us-gaap:CommonStockMember2026-06-300001287098us-gaap:CommonStockMember2026-03-310001287098us-gaap:CommonStockMember2025-12-310001287098us-gaap:CommonStockMember2025-09-300001287098us-gaap:CommonStockMember2025-06-300001287098us-gaap:CommonStockMember2025-03-310001287098us-gaap:CommonStockMember2024-12-310001287098us-gaap:EmployeeStockOptionMember2026-07-012026-09-300001287098us-gaap:EmployeeStockOptionMember2025-01-012025-09-300001287098us-gaap:EmployeeStockOptionMember2025-07-012025-09-300001287098mxct:InducementPlan2026Member2026-09-300001287098mxct:EquityIncentivePlan2022Member2026-09-300001287098mxct:EquityIncentivePlan2022Member2025-12-310001287098mxct:EquityIncentivePlan2022Member2025-06-182025-06-180001287098mxct:EquityIncentivePlan2022Member2024-06-112024-06-110001287098mxct:EquityIncentivePlan2022Member2023-06-222023-06-220001287098us-gaap:RestrictedStockUnitsRSUMember2026-07-012026-09-300001287098us-gaap:RestrictedStockUnitsRSUMember2026-01-012026-09-300001287098us-gaap:RestrictedStockUnitsRSUMember2025-07-012025-09-300001287098us-gaap:RestrictedStockUnitsRSUMember2025-01-012025-09-300001287098us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2026-01-012026-09-300001287098us-gaap:NonUsMember2026-07-012026-09-300001287098country:US2026-07-012026-09-300001287098us-gaap:NonUsMember2026-01-012026-09-300001287098country:US2026-01-012026-09-300001287098us-gaap:NonUsMember2025-07-012025-09-300001287098country:US2025-07-012025-09-300001287098us-gaap:NonUsMember2025-01-012025-09-300001287098country:US2025-01-012025-09-300001287098mxct:AssayAndOtherServiceRevenueMember2026-10-012026-09-3000012870982029-10-012026-09-3000012870982028-10-012026-09-3000012870982027-10-012026-09-3000012870982026-10-012026-09-300001287098us-gaap:ProductMember2026-07-012026-09-300001287098mxct:AssayAndOtherServiceRevenueMember2026-07-012026-09-300001287098us-gaap:ProductMember2026-01-012026-09-300001287098mxct:AssayAndOtherServiceRevenueMember2026-01-012026-09-300001287098us-gaap:ProductMember2025-07-012025-09-300001287098mxct:AssayAndOtherServiceRevenueMember2025-07-012025-09-300001287098us-gaap:ProductMember2025-01-012025-09-300001287098mxct:AssayAndOtherServiceRevenueMember2025-01-012025-09-300001287098us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2026-09-300001287098us-gaap:LeaseholdsAndLeaseholdImprovementsMember2026-09-300001287098us-gaap:FurnitureAndFixturesMember2026-09-300001287098us-gaap:ConstructionInProgressMember2026-09-300001287098mxct:InstrumentsMember2026-09-300001287098us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2025-12-310001287098us-gaap:LeaseholdsAndLeaseholdImprovementsMember2025-12-310001287098us-gaap:FurnitureAndFixturesMember2025-12-310001287098us-gaap:ConstructionInProgressMember2025-12-310001287098mxct:InstrumentsMember2025-12-310001287098us-gaap:LicenseMember2026-07-012026-09-300001287098us-gaap:LicenseMember2026-01-012026-09-300001287098us-gaap:LicenseMember2025-07-012025-09-300001287098us-gaap:LicenseMember2025-01-012025-09-300001287098us-gaap:RetainedEarningsMember2026-07-012026-09-300001287098us-gaap:RetainedEarningsMember2026-04-012026-06-300001287098us-gaap:RetainedEarningsMember2026-01-012026-03-310001287098us-gaap:RetainedEarningsMember2025-07-012025-09-300001287098us-gaap:RetainedEarningsMember2025-04-012025-06-300001287098us-gaap:RetainedEarningsMember2025-01-012025-03-310001287098srt:MinimumMember2026-09-300001287098srt:MaximumMember2026-09-300001287098us-gaap:TradeNamesMember2026-09-300001287098us-gaap:DevelopedTechnologyRightsMember2026-09-300001287098us-gaap:CustomerRelationshipsMember2026-09-300001287098us-gaap:TradeNamesMember2025-12-310001287098us-gaap:DevelopedTechnologyRightsMember2025-12-310001287098us-gaap:CustomerRelationshipsMember2025-12-310001287098us-gaap:FairValueMeasurementsRecurringMember2026-09-300001287098us-gaap:FairValueMeasurementsRecurringMember2025-12-310001287098us-gaap:EmployeeStockOptionMember2026-09-300001287098us-gaap:EmployeeStockOptionMember2026-01-012026-09-300001287098us-gaap:FairValueMeasurementsNonrecurringMemberus-gaap:CorporateDebtSecuritiesMember2026-09-300001287098us-gaap:FairValueMeasurementsNonrecurringMemberus-gaap:CommercialPaperMember2026-09-300001287098us-gaap:FairValueMeasurementsNonrecurringMembermxct:UsTreasurySecuritiesAndGovernmentAgencyBondsShortTermInvestmentsMember2026-09-300001287098us-gaap:FairValueMeasurementsNonrecurringMembermxct:UsTreasurySecuritiesAndGovernmentAgencyBondsLongTermInvestmentsMember2026-09-300001287098us-gaap:FairValueMeasurementsNonrecurringMembermxct:CorporateDebtShortTermInvestmentsMember2026-09-300001287098us-gaap:FairValueMeasurementsNonrecurringMember2026-09-300001287098us-gaap:FairValueMeasurementsNonrecurringMemberus-gaap:CorporateDebtSecuritiesMember2025-12-310001287098us-gaap:FairValueMeasurementsNonrecurringMemberus-gaap:CommercialPaperMember2025-12-310001287098us-gaap:FairValueMeasurementsNonrecurringMembermxct:UsTreasurySecuritiesAndGovernmentAgencyBondsShortTermInvestmentsMember2025-12-310001287098us-gaap:FairValueMeasurementsNonrecurringMembermxct:UsTreasurySecuritiesAndGovernmentAgencyBondsLongTermInvestmentsMember2025-12-310001287098us-gaap:FairValueMeasurementsNonrecurringMembermxct:CorporateDebtShortTermInvestmentsMember2025-12-310001287098us-gaap:FairValueMeasurementsNonrecurringMember2025-12-310001287098us-gaap:SubsequentEventMember2026-11-092026-11-090001287098us-gaap:SecuredDebtMembermxct:SeniorSecuredTermLoanTranche1Memberus-gaap:SubsequentEventMember2026-11-090001287098us-gaap:RevolvingCreditFacilityMemberus-gaap:SubsequentEventMember2026-11-092026-11-090001287098mxct:CustomerMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2026-07-012026-09-300001287098mxct:CustomerBMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2026-07-012026-09-300001287098us-gaap:AccountsPayableMemberus-gaap:SupplierConcentrationRiskMembermxct:SupplierOneMember2026-01-012026-09-300001287098mxct:CustomerMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2026-01-012026-09-300001287098mxct:CustomerMemberus-gaap:AccountsReceivableMemberus-gaap:CreditConcentrationRiskMember2026-01-012026-09-300001287098mxct:CustomerCMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2026-01-012026-09-300001287098mxct:CustomerMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2025-07-012025-09-300001287098us-gaap:AccountsPayableMemberus-gaap:SupplierConcentrationRiskMembermxct:SupplierOneMember2025-01-012025-12-310001287098mxct:CustomerMemberus-gaap:AccountsReceivableMemberus-gaap:CreditConcentrationRiskMember2025-01-012025-12-310001287098mxct:CustomerMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2025-01-012025-09-3000012870982025-09-3000012870982024-12-310001287098mxct:SequreIncMember2025-01-310001287098mxct:AkronBioproductsLlcMemberus-gaap:SubsequentEventMember2026-11-092026-11-090001287098us-gaap:SellingAndMarketingExpense2026-07-012026-09-300001287098us-gaap:ResearchAndDevelopmentExpense2026-07-012026-09-300001287098us-gaap:GeneralAndAdministrativeExpense2026-07-012026-09-300001287098us-gaap:SellingAndMarketingExpense2026-01-012026-09-300001287098us-gaap:ResearchAndDevelopmentExpense2026-01-012026-09-300001287098us-gaap:GeneralAndAdministrativeExpense2026-01-012026-09-300001287098us-gaap:SellingAndMarketingExpense2025-07-012025-09-300001287098us-gaap:ResearchAndDevelopmentExpense2025-07-012025-09-300001287098us-gaap:GeneralAndAdministrativeExpense2025-07-012025-09-300001287098us-gaap:SellingAndMarketingExpense2025-01-012025-09-300001287098us-gaap:ResearchAndDevelopmentExpense2025-01-012025-09-300001287098us-gaap:GeneralAndAdministrativeExpense2025-01-012025-09-300001287098us-gaap:AdditionalPaidInCapitalMember2026-07-012026-09-300001287098us-gaap:AdditionalPaidInCapitalMember2026-04-012026-06-3000012870982026-04-012026-06-300001287098us-gaap:AdditionalPaidInCapitalMember2026-01-012026-03-3100012870982026-01-012026-03-310001287098us-gaap:AdditionalPaidInCapitalMember2025-07-012025-09-3000012870982025-07-012025-09-300001287098us-gaap:AdditionalPaidInCapitalMember2025-04-012025-06-3000012870982025-04-012025-06-300001287098us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-3100012870982025-01-012025-03-310001287098us-gaap:TradeNamesMember2026-01-012026-09-300001287098us-gaap:DevelopedTechnologyRightsMember2026-01-012026-09-300001287098us-gaap:CustomerRelationshipsMember2026-01-012026-09-3000012870982026-05-310001287098mxct:EquityIncentivePlan2022Member2022-05-310001287098mxct:EmployeeStockPurchasePlan2021Member2026-09-300001287098us-gaap:SecuredDebtMemberus-gaap:SubsequentEventMember2026-11-092026-11-090001287098us-gaap:InventoriesMemberus-gaap:SupplierConcentrationRiskMembermxct:SupplierOneMember2026-07-012026-09-300001287098us-gaap:InventoriesMemberus-gaap:SupplierConcentrationRiskMembermxct:SupplierOneMember2026-01-012026-09-300001287098us-gaap:InventoriesMemberus-gaap:SupplierConcentrationRiskMembermxct:SupplierOneMember2025-07-012025-09-300001287098us-gaap:InventoriesMemberus-gaap:SupplierConcentrationRiskMembermxct:SupplierOneMember2025-01-012025-09-3000012870982025-01-012025-09-300001287098mxct:EmployeeStockPurchasePlan2021Member2026-01-012026-09-300001287098srt:MinimumMember2026-01-012026-09-300001287098srt:MaximumMember2026-01-012026-09-300001287098us-gaap:SecuredDebtMemberus-gaap:SubsequentEventMember2026-11-090001287098us-gaap:RevolvingCreditFacilityMemberus-gaap:SubsequentEventMember2026-11-090001287098us-gaap:SubsequentEventMember2026-11-090001287098mxct:CellEngineeringTechnologySegmentMember2026-07-012026-09-300001287098mxct:CellEngineeringTechnologySegmentMember2026-01-012026-09-300001287098mxct:CellEngineeringTechnologySegmentMember2025-07-012025-09-300001287098mxct:CellEngineeringTechnologySegmentMember2025-01-012025-09-300001287098mxct:InducementPlan2026Member2026-03-310001287098mxct:AkronBioproductsLlcMemberus-gaap:SubsequentEventMember2026-11-0900012870982026-09-3000012870982025-12-3100012870982026-07-012026-09-3000012870982026-11-0600012870982026-01-012026-09-30xbrli:sharesiso4217:USDxbrli:puremxct:itemmxct:trancheiso4217:USDxbrli:sharesmxct:segment

Table of Contents

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark one)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2026

or

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from___ to___

Commission File Number: 001-40674

MaxCyte, Inc.

(Exact name of registrant as specified in its charter)

​

​

Delaware

​

52-2210438

(State or other jurisdiction of incorporation or organization)

 

(I.R.S. Employer Identification No.)

​

9713 Key West Avenue, Suite 400

Rockville, Maryland 20850

(Address of principal executive offices including zip code)

Registrant’s telephone number, including area code: (301) 944-1700

​

N/A

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

​

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common stock, par value $0.01 per share

MXCT

The Nasdaq Stock Market LLC

​

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes☒ No☐

​

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

​

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

☐

Accelerated filer

☐

Non-accelerated filer

☒

Smaller reporting company

☒

Emerging growth company

☒

​

​

​

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

​

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of November 6, 2026, the registrant had 103,250,292 shares of common stock, $0.01 par value per share, issued and outstanding.

​

​

Table of Contents

Table of Contents

​

​

Page No

PART I. FINANCIAL INFORMATION

3

Item 1.

Condensed Consolidated Financial Statements (Unaudited)

3

​

Condensed Consolidated Balance Sheets

3

​

Condensed Consolidated Statements of Operations and Comprehensive Loss

4

​

Condensed Consolidated Statements of Changes in Stockholders’ Equity

5

​

Condensed Consolidated Statements of Cash Flows

6

​

Notes to Unaudited Condensed Consolidated Financial Statements

7

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

18

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

33

Item 4.

Controls and Procedures

34

PART II. OTHER INFORMATION

35

Item 1.

Legal Proceedings

35

Item 1A.

Risk Factors

35

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

36

Item 3.

Defaults Upon Senior Securities

37

Item 4.

Mine Safety Disclosures

37

Item 5.

Other Information

37

Item 6.

Exhibits

38

Signatures

39

​

​

​

2

Table of Contents

PART I. FINANCIAL INFORMATION

Item 1. Condensed Consolidated Financial Statements (Unaudited)

​

MaxCyte, Inc.

Condensed Consolidated Balance Sheets

(in thousands, except share and per share amounts)

​

​

​

​

​

​

​

​

​

September 30, 

​

December 31, 

​

  ​ ​ ​

2026

  ​ ​ ​

2025

​

​

​

​

​

​

(See Note 2)

Assets

 

​

​

​

​

​

Current assets:

 

​

  ​

 

​

  ​

Cash and cash equivalents

​

$

13,372

​

$

20,065

Short-term investments, at amortized cost

​

 

87,908

​

 

82,979

Accounts receivable, net

​

 

12,054

​

 

3,503

Inventory, net

​

 

7,380

​

 

7,547

Prepaid expenses and other current assets

​

 

3,777

​

 

4,275

Assets held for sale

​

​

180

​

​

—

Total current assets

​

 

124,671

​

 

118,369

​

​

​

​

​

​

​

Investments, non-current, at amortized cost

​

​

31,469

​

​

52,570

Property and equipment, net

​

​

14,342

​

 

17,531

Right-of-use asset - operating leases

​

​

10,237

​

 

10,920

Intangible assets, net

​

​

749

​

​

650

Other assets

​

 

1,015

​

 

2,467

Total assets

​

$

182,483

​

$

202,507

​

​

​

​

​

​

​

Liabilities and stockholders’ equity

​

 

  ​

​

 

  ​

Current liabilities:

​

 

  ​

​

 

  ​

Accounts payable

​

$

1,026

​

$

1,401

Accrued expenses and other

​

 

5,937

​

 

7,812

Operating lease liability, current

​

 

1,565

​

 

1,456

Deferred revenue, current portion

​

 

7,388

​

 

3,598

Total current liabilities

​

 

15,916

​

 

14,267

​

​

​

​

​

​

​

Operating lease liability, net of current portion

​

 

15,325

​

 

16,487

Other liabilities

​

 

311

​

 

263

Total liabilities

​

 

31,552

​

 

31,017

​

​

​

​

​

​

​

Commitments and contingencies (Note 7)

​

 

  ​

​

 

  ​

Stockholders’ equity:

​

 

  ​

​

 

  ​

Preferred stock, $0.01 par value; 5,000,000 shares authorized and no shares issued and outstanding at September 30, 2026 and December 31, 2025

​

​

—

​

​

—

Common stock, $0.01 par value; 400,000,000 shares authorized, 107,493,772 and 106,789,618 shares issued, and 103,233,238 and 106,789,618 outstanding at September 30, 2026 and December 31, 2025, respectively

​

​

1,075

​

​

1,068

Additional paid-in capital

​

 

435,225

​

 

431,905

Treasury stock, 4,260,534 shares, at cost

​

​

(5,500)

​

​

—

Accumulated deficit

​

 

(279,869)

​

 

(261,483)

Total stockholders’ equity

​

 

150,931

​

 

171,490

Total liabilities and stockholders’ equity

​

$

182,483

​

$

202,507

​

See accompanying notes to unaudited condensed consolidated financial statements.

​

3

Table of Contents

MaxCyte, Inc.

Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except share and per share amounts)

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

  ​ ​ ​

Three Months Ended September 30, 

​

Nine Months Ended September 30, 

​

​

2026

  ​ ​ ​

2025

  ​ ​ ​

2026

  ​ ​ ​

2025

Revenue

​

$

10,152

​

$

6,829

​

$

27,074

​

$

25,726

Cost of goods sold

​

 

1,684

​

 

1,596

​

 

4,928

​

 

4,612

Gross profit

​

 

8,468

​

 

5,233

​

 

22,146

​

 

21,114

​

​

​

​

​

​

​

​

​

​

​

​

​

Operating expenses:

​

 

  ​

​

 

  ​

​

 

  ​

​

 

  ​

Research and development

​

 

2,874

​

 

5,316

​

 

10,984

​

 

17,488

Sales and marketing

​

 

4,214

​

 

3,936

​

 

11,006

​

 

15,420

General and administrative

​

 

6,553

​

 

6,028

​

 

19,777

​

 

22,634

Restructuring expense

​

​

—

​

​

3,058

​

​

—

​

​

3,058

Depreciation and amortization

​

​

868

​

​

1,044

​

​

2,837

​

​

3,185

Total operating expenses

​

 

14,509

​

 

19,382

​

 

44,604

​

 

61,785

Operating loss

​

 

(6,041)

​

 

(14,149)

​

 

(22,458)

​

 

(40,671)

​

​

​

​

​

​

​

​

​

​

​

​

​

Other income:

​

 

  ​

​

 

  ​

​

 

  ​

​

 

  ​

Interest income

​

 

1,279

​

 

1,733

​

 

4,072

​

 

5,637

Total other income

​

 

1,279

​

 

1,733

​

 

4,072

​

 

5,637

Loss before income taxes

​

​

(4,762)

​

​

(12,416)

​

​

(18,386)

​

​

(35,034)

Provision for income taxes

​

​

—

​

​

—

​

​

—

​

​

—

Net loss

​

​

(4,762)

​

​

(12,416)

​

​

(18,386)

​

​

(35,034)

Other comprehensive income

​

​

—

​

​

—

​

​

—

​

​

—

Comprehensive loss

​

$

(4,762)

​

$

(12,416)

​

$

(18,386)

​

$

(35,034)

Basic and diluted net loss per share

​

$

(0.05)

​

$

(0.12)

​

$

(0.17)

​

$

(0.33)

Weighted-average shares outstanding, basic and diluted

​

 

103,537,926

​

 

106,613,075

​

 

105,732,991

​

 

106,324,792

​

​

See accompanying notes to unaudited condensed consolidated financial statements.

​

4

Table of Contents

MaxCyte, Inc.

Unaudited Condensed Consolidated Statements of Changes in Stockholders’ Equity

(in thousands, except share amounts)

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Total 

​

​

Common Stock

​

Additional

​

Treasury

​

Accumulated 

​

Stockholders’

​

  ​ ​ ​

Shares

  ​ ​ ​

Amount

  ​ ​ ​

Paid-in Capital

  ​ ​ ​

Stock

  ​ ​ ​

Deficit

  ​ ​ ​

 Equity

Balance at January 1, 2025

 

105,711,093

​

$

1,057

​

$

422,047

​

$

—

​

$

(216,853)

​

$

206,251

Stock-based compensation expense

 

—

​

 

—

​

 

3,039

​

 

—

​

 

—

​

 

3,039

Exercise of stock options

​

290,993

​

​

3

​

​

380

​

​

—

​

​

—

​

​

383

Vesting of restricted stock units

​

311,632

​

​

3

​

​

(3)

​

​

—

​

​

—

​

​

—

Net loss

 

—

​

 

—

​

 

—

​

 

—

​

 

(10,261)

​

 

(10,261)

Balance at March 31, 2025

 

106,313,718

​

​

1,063

​

​

425,463

​

​

—

​

​

(227,114)

​

​

199,412

Stock-based compensation expense

​

—

​

​

—

​

​

3,514

​

​

—

​

​

—

​

​

3,514

Exercise of stock options

 

18,542

​

 

—

​

 

20

​

 

—

​

 

—

​

 

20

Vesting of restricted stock units

​

191,700

​

​

2

​

​

(2)

​

​

—

​

​

—

​

​

—

Issuance of common stock under
employee stock purchase plan

​

68,179

​

​

1

​

​

133

​

​

—

​

​

—

​

​

134

Net loss

 

—

​

 

—

​

 

—

​

 

—

​

 

(12,357)

​

 

(12,357)

Balance at June 30, 2025

 

106,592,139

​

​

1,066

​

​

429,128

​

​

—

​

​

(239,471)

​

​

190,723

Stock-based compensation expense

​

—

​

​

—

​

​

1,954

​

​

—

​

​

—

​

​

1,954

Exercise of stock options

​

14,442

​

​

—

​

​

14

​

​

—

​

​

—

​

​

14

Vesting of restricted stock units

​

37,762

​

​

—

​

​

—

​

​

—

​

​

—

​

​

—

Net loss

​

—

​

​

—

​

​

—

​

​

—

​

​

(12,416)

​

​

(12,416)

Balance at September 30, 2025

​

106,644,343

​

$

1,066

​

$

431,096

​

$

—

​

$

(251,887)

​

$

180,275

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Total 

​

​

Common Stock

​

Additional

​

Treasury

​

Accumulated 

​

Stockholders’

​

  ​ ​ ​

Shares

  ​ ​ ​

Amount

  ​ ​ ​

Paid-in Capital

  ​ ​ ​

Stock

  ​ ​ ​

Deficit

  ​ ​ ​

 Equity

Balance at January 1, 2026

 

106,789,618

​

$

1,068

​

$

431,905

​

$

—

​

$

(261,483)

​

$

171,490

Stock-based compensation expense

 

—

​

 

—

​

 

1,141

​

 

—

​

 

—

​

 

1,141

Exercise of stock options

​

4,814

​

​

—

​

​

5

​

​

—

​

​

—

​

​

5

Vesting of restricted stock units

​

327,240

​

​

3

​

​

(3)

​

​

—

​

​

—

​

​

—

Net loss

 

—

​

 

—

​

 

—

​

 

—

​

 

(4,750)

​

 

(4,750)

Balance at March 31, 2026

 

107,121,672

​

​

1,071

​

​

433,048

​

​

—

​

​

(266,233)

​

​

167,886

Stock-based compensation expense

 

—

​

 

—

​

 

1,160

​

 

—

​

 

—

​

 

1,160

Exercise of stock options

​

24,634

​

​

—

​

​

24

​

​

—

​

​

—

​

​

24

Vesting of restricted stock units

​

262,655

​

​

3

​

​

(3)

​

​

—

​

​

—

​

​

—

Issuance of common stock under
employee stock purchase plan

​

38,116

​

​

—

​

​

34

​

​

—

​

​

—

​

​

34

Repurchases of common stock

​

​

​

​

​

​

​

​

​

​

(1,478)

​

​

​

​

​

(1,478)

Net loss

 

—

​

 

—

​

 

—

​

 

—

​

​

(8,874)

​

 

(8,874)

Balance at June 30, 2026

 

107,447,077

​

​

1,074

​

​

434,263

​

​

(1,478)

​

​

(275,107)

​

$

158,752

Stock-based compensation expense

​

—

​

​

—

​

​

963

​

​

—

​

​

—

​

​

963

Vesting of restricted stock units

​

46,695

​

​

1

​

​

(1)

​

​

—

​

​

—

​

​

—

Exercise of stock options

​

—

​

​

—

​

​

—

​

​

—

​

​

—

​

​

—

Repurchases of common stock

​

—

​

​

—

​

​

—

​

​

(4,022)

​

​

—

​

​

(4,022)

Net loss

​

—

​

​

—

​

​

—

​

​

—

​

​

(4,762)

​

​

(4,762)

Balance at September 30, 2026

​

107,493,772

​

$

1,075

​

$

435,225

​

$

(5,500)

​

$

(279,869)

​

$

150,931

​

See accompanying notes to unaudited condensed consolidated financial statements.

​

5

Table of Contents

MaxCyte, Inc.

Unaudited Condensed Consolidated Statements of Cash Flows

(in thousands)

​

​

​

​

​

​

​

​

​

  ​ ​ ​

Nine Months Ended September 30, 

​

​

​

2026

  ​ ​ ​

2025

​

Cash flows from operating activities:

 

​

  ​

 

​

  ​

 

Net loss

​

$

(18,386)

​

$

(35,034)

​

​

​

​

​

​

​

​

​

Adjustments to reconcile net loss to net cash used in operating activities:

​

 

​

​

 

​

​

Depreciation and amortization

​

 

2,925

​

 

3,268

​

Impairment of fixed assets

​

​

630

​

​

—

​

Lease right-of-use asset amortization

​

​

683

​

​

587

​

Net book value of consigned equipment sold

​

 

105

​

 

70

​

Loss on disposal of property and equipment

​

​

23

​

​

132

​

Stock-based compensation

​

 

3,264

​

 

8,507

​

Credit loss expense

​

​

—

​

​

29

​

Provision for inventory reserve

​

​

400

​

​

525

​

Amortization of discounts on investments

​

 

(1,251)

​

 

(2,219)

​

​

​

​

​

​

​

​

​

Changes in operating assets and liabilities, net of effects of acquisition:

​

 

​

​

 

​

​

Accounts receivable

​

 

(8,551)

​

 

(3,649)

​

Inventory

​

 

(708)

​

 

647

​

Prepaid expense and other current assets

​

 

498

​

 

744

​

Other assets

​

 

1,464

​

 

(924)

​

Accounts payable, accrued expenses and other

​

 

(2,217)

​

 

(3,338)

​

Operating lease liability

​

 

(1,053)

​

 

(939)

​

Deferred revenue

​

 

3,790

​

 

(80)

​

Other liabilities

​

 

48

​

 

(47)

​

Net cash used in operating activities

​

 

(18,336)

​

 

(31,721)

​

​

​

​

​

​

​

​

​

Cash flows from investing activities:

​

 

  ​

​

 

  ​

​

Purchases of investments

​

 

(55,113)

​

​

(98,031)

​

Maturities of investments

​

 

72,536

​

​

117,600

​

Purchases of property and equipment

​

 

(193)

​

​

(1,537)

​

Acquisition of intangible assets

​

​

(150)

​

​

—

​

Acquisition of business, net of cash acquired of $541

​

​

—

​

​

(1,773)

​

Net cash provided by investing activities

​

 

17,080

​

 

16,259

​

​

​

​

​

​

​

​

​

Cash flows from financing activities:

​

 

  ​

​

 

  ​

​

Proceeds from exercise of stock options

​

 

29

​

​

417

​

Proceeds from issuance of common stock under employee stock purchase plan

​

​

34

​

​

134

​

Repurchases of common stock

​

​

(5,500)

​

​

—

​

Net cash (used in) provided by financing activities

​

 

(5,437)

​

 

551

​

Net decrease in cash and cash equivalents

​

 

(6,693)

​

 

(14,911)

​

Cash and cash equivalents, beginning of period

​

 

20,065

​

 

27,884

​

Cash and cash equivalents, end of period

​

$

13,372

​

$

12,973

​

​

​

​

​

​

​

​

​

Supplemental cash flow information:

​

 

  ​

​

 

  ​

​

Property and equipment purchases included in accounts payable and accrued expenses

​

$

—

​

$

29

​

Right-of-use assets obtained in business combination by assumption of lease liabilities

​

$

—

​

$

956

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

See accompanying notes to unaudited condensed consolidated financial statements.

​

​

6

Table of Contents

MaxCyte, Inc.

Notes to Unaudited Condensed Consolidated Financial Statements

(in thousands, except par value, share and per share amounts, or as otherwise indicated)

​

1.   Organization and Description of Business

MaxCyte, Inc. (the “Company” or “MaxCyte”) is a global life sciences company focused on providing comprehensive cell engineering solutions to advance the discovery, development, and commercialization of next-generation cell therapies. The Company’s enabling platform technologies, including its proprietary Flow Electroporation® technology, support academic institutions, research centers, and biotechnology and pharmaceutical company customers who are engaged in cell therapy, including gene-editing and immuno-oncology, as well as in drug discovery and development and biomanufacturing.

As a scalable cell engineering solutions provider, the Company licenses and sells its instruments and technology, sells its related processing assemblies (“PAs”) and consumables, and provides on target and off-target gene-editing characterization assessment services (“Assay Services”).  The Company also enters into strategic platform license agreements (“SPLs”) with customers in clinical and commercial manufacturing which may include development milestones and potential royalties.

2.    Summary of Significant Accounting Policies

Basis of Presentation

The accompanying unaudited condensed consolidated interim financial statements have been prepared in accordance with accounting principles generally accepted in the U.S. (“U.S. GAAP”) for interim financial information and pursuant to the instructions to Form 10-Q and Article 8 of Regulation S-X of the U.S. Securities and Exchange Commission (the “SEC”). In the Company’s opinion, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of both normal recurring adjustments, and adjustments for material unusual or infrequently occurring transactions or events, which are necessary to present fairly the Company’s financial position, results of operations, and cash flows as of and for the periods presented. The condensed consolidated balance sheet at December 31, 2025 has been derived from audited consolidated financial statements as of that date. The unaudited condensed consolidated financial statements are not necessarily indicative of the results that may occur for the full fiscal year or any other future year or period. Certain information and notes disclosure normally included in the consolidated financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to instructions, rules, and regulations prescribed by the SEC. The Company believes that the disclosures provided herein are adequate to make the information presented not misleading when these unaudited interim condensed consolidated financial statements are read in conjunction with the audited consolidated financial statements and notes included in the Company’s Annual Report on Form 10-K filed with the SEC on March 25, 2026 (the “2025 Form 10-K”).

​

Significant Accounting Policies

The Company’s significant accounting policies are disclosed in the notes to its audited consolidated financial statements for the year ended December 31, 2025 included in the 2025 Form 10-K and have not materially changed during the three and nine months ended September 30, 2026.

Basis of Consolidation

The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, CCTI Inc. SeQure Dx Inc. (“SeQure”), previously a wholly-owned subsidiary of the Company, was merged with and into the Company. All significant intercompany balances and transactions have been eliminated in consolidation.

7

Table of Contents

Concentration of Risk

The Company maintains its cash and cash equivalents with financial institutions that management believes to be of high credit quality. At times, the Company’s cash balances may exceed federally insured limits and cash may also be deposited in foreign bank accounts that are not covered by federal deposit insurance. The Company does not believe that this results in any significant credit risk beyond the normal credit risk associated with commercial banking relationships.

Significant customers are those that accounted for 10% or more of the Company’s total revenue for the period or accounts receivable as of the end of a reporting period.

Significant customers that represented 10% or more of revenue are set forth in the following table:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

  ​ ​ ​

Three months ended September 30, 

​

Nine months ended September 30, 

 

​

​

2026

  ​ ​ ​

2025

​

2026

  ​ ​ ​

2025

​

Customer A

​

​

32

%

​

28

%

​

29

%

​

27

%

Customer B

​

 

10

%

 

*

​

 

*

​

 

*

​

Customer C

​

 

*

​

 

*

​

 

15

%

 

*

​

*Customer accounted for less than 10% of revenue for the respective period.

As of September 30, 2026 and December 31, 2025, Customer A accounted for 54% and 18% of the Company’s accounts receivable.  

​

Certain components included in the Company’s products are obtained from a single source or a limited group of suppliers. During the three months ended September 30, 2026 and 2025, 11% and 8%, respectively, of the Company’s additions to inventory were from one supplier. During the nine months ended September 30, 2026 and 2025, 13% and 12%, respectively, of the Company’s additions to inventory were from one supplier. At September 30, 2026 and December 31, 2025, this supplier accounted for 12% and 10% of accounts payable, respectively.  

Accounts Receivable

Accounts receivable are recorded net of an allowance for expected credit losses.  The Company recorded an allowance for credit losses of an amount equal to anticipated future write-offs. The Company recorded an allowance for expected credit losses of $6 at September 30, 2026 and December 31, 2025.   Accounts receivable include both trade and lease receivables.  Lease receivables arising from operating leases of the Company’s electroporation technology are evaluated for collectability in accordance with Accounting Standards Codification (“ASC”) 842, Leases, and therefore are not included in the Company's allowance for expected credit losses.

Deferred Asset Acquisition Costs

The Company capitalizes incurred direct, incremental costs related to potential transactions that, if consummated, would be accounted for as an asset acquisition under ASC 805-50. These costs primarily consist of professional fees, including legal, advisory, accounting, and other transaction-specific services that are directly attributable to the contemplated acquisition and included in other assets on the Company’s balance sheet.  During the nine months ended September 30, 2026, the Company decided not to pursue continued evaluation of a certain asset acquisition and recorded a charge of $1,582 related to previously capitalized costs in general and administrative expenses in the condensed consolidated statement of operations.  

Intangible Assets

The Company recognizes acquired intangible assets at fair value on the date of acquisition.  Intangible assets with finite lives are amortized over their useful lives using the straight-line method.  The useful lives of the Company’s intangible assets range from seven to 15 years.    

8

Table of Contents

Foreign Currency

The Company’s functional currency is the U.S. dollar; transactions denominated in foreign currencies are subject to currency risk. The Company recognized $65 and $11 in foreign currency losses for the three months ended September 30, 2026 and 2025, respectively, and $215 and $4 in foreign currency losses for the nine months ended September 30, 2026 and 2025, respectively.

Leases

For transactions in which the Company is the lessee, at the inception of a contract, the Company determines if the arrangement is, or contains, a lease. See Note 7 for additional details about leases under which the Company is the lessee.

All transactions in which the Company is the lessor are short-term (one year or less) and have been classified as operating leases. All leases require upfront payments covering the full period of the lease and thus, there are no future payments expected to be received from existing leases. See Note 3 for details on revenue recognition related to lease agreements.

Loss Per Share

Basic loss per share is computed by dividing net loss available to common stockholders by the weighted-average number of shares of common stock outstanding during the period.

For periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all dilutive potential common shares is anti-dilutive. The number of anti-dilutive shares excluded from the computation of diluted loss per share, consisting of shares of underlying stock options, restricted stock units, performance stock units, and shares under employee stock purchase plans was 17.3 million for the three and nine months ended September 30, 2026 and 18.1 million for the three and nine months ended September 30, 2025.

Recent Accounting Pronouncements

New Accounting Pronouncement Recently Adopted

In January 2026, the Company adopted the Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”)  2025-05, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets (“ASU 2025-05”). ASU 2025-05 provides a practical expedient that all entities can use when estimating expected credit losses, which permits an entity to assume that the current conditions it has applied in determining credit loss allowances remain unchanged for the remaining life of those assets. The adoption of this guidance did not have a material impact on the Company’s unaudited condensed consolidated financial statements and disclosures.

New Accounting Pronouncement Not Yet Adopted

In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (“ASU 2024-03”). The amendments in ASU 2024-03 improve the transparency of expenses by nature by requiring additional disaggregated expense disclosures. The Company is in the process of evaluating the information and reporting process necessary to comply with the new disclosure requirements, which are effective beginning with the Company’s 2027 annual financial statements.  

3.    Revenue

The Company generates revenue from the sale of instruments and related PAs and consumables, licenses of its proprietary technology, and Assay Services. Under SPL agreements, which include annual license payments, the Company also generates revenue according to achievement of the customer’s associated clinical progress milestones and sales-based royalty payments. Certain customer arrangements include multiple goods and services, including licenses, instruments, consumables, and services.

9

Table of Contents

The Company accounts for revenue from contracts with customers in accordance with ASC 606, Revenue from Contracts with Customers, and its licensed revenue for leased technology and equipment under ASC 842, Leases. Contracts with customers may contain one or more distinct performance obligations. For contracts with multiple performance obligations, the Company allocates the transaction price to each performance obligation based on its relative standalone selling price.

Revenue is recognized when, or as, control of the promised goods or services transfers to the customer in an amount that reflects the consideration the Company expects to receive in exchange for those goods or services.

Revenue from the sale of instruments, PAs, and consumables is generally recognized upon shipment to the customer. Revenue from Assay Services is recognized when performance obligations have been met, typically upon delivery of the characterization report. Revenue associated with extended warranties and other service arrangements is recognized when the related performance obligations are satisfied.

The Company enters into SPL arrangements with customers developing cell therapies for clinical or commercial use. These arrangements may include licenses of proprietary technology, milestone payments, sales-based royalties, and sales or leases of instruments. Depending on the nature of the arrangement, the Company accounts for the applicable components under ASC 842, Leases, or ASC 606, Revenue from Contracts with Customers.

Revenue from lease components is generally recognized over the applicable lease term, with variable payments recognized when the events or conditions giving rise to those payments occur. Revenue from licenses of intellectual property accounted for as contracts with customers is recognized either at a point in time or over time, depending on the nature of the license and the Company's ongoing obligations. Milestone payments associated with these licenses are recognized when it is probable that a significant reversal of cumulative revenue recognized will not occur, generally upon achievement of the applicable milestone. Sales-based royalties associated with intellectual property licenses are generally recognized when the underlying customer sales occur.

Disaggregation of Revenue

The following table depicts the disaggregation of revenue by type of contract:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three months ended September 30, 2026

​

Nine months ended September 30, 2026

​

​

Revenue from

​

Revenue

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Contracts

​

from

​

​

​

Revenue from

​

Revenue

​

​

​

​

​

 with

​

Lease

​

Total

​

Contracts with

​

from Lease

​

Total

​

  ​ ​ ​

Customers

  ​ ​ ​

Elements

  ​ ​ ​

Revenue

  ​ ​ ​

Customers

  ​ ​ ​

Elements

  ​ ​ ​

Revenue

Product sales

​

$

5,871

​

$

—

​

$

5,871

​

$

13,608

​

$

—

​

$

13,608

Licenses

​

 

6

​

 

3,956

​

 

3,962

​

 

641

​

 

11,441

​

 

12,082

Assay and other service revenue

​

 

319

​

 

—

​

 

319

​

 

1,384

​

 

—

​

 

1,384

Total

​

$

6,196

​

$

3,956

​

$

10,152

​

$

15,633

​

$

11,441

​

$

27,074

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three months ended September 30, 2025

​

Nine months ended September 30, 2025

​

​

Revenue from

​

Revenue

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Contracts

​

from

​

​

​

Revenue from

​

Revenue

​

​

​

​

​

 with

​

Lease

​

Total

​

Contracts with

​

from Lease

​

Total

​

  ​ ​ ​

Customers

  ​ ​ ​

Elements

  ​ ​ ​

Revenue

  ​ ​ ​

Customers

  ​ ​ ​

Elements

  ​ ​ ​

Revenue

Product sales

​

$

3,953

​

$

—

​

$

3,953

​

$

14,538

​

$

—

​

$

14,538

Licenses

​

 

—

​

 

2,226

​

 

2,226

​

 

275

​

 

9,556

​

 

9,831

Assay and other service revenue

​

 

650

​

 

—

​

 

650

​

 

1,357

​

 

—

​

 

1,357

Total

​

$

4,603

​

$

2,226

​

$

6,829

​

$

16,170

​

$

9,556

​

$

25,726

​

Additional Disclosures Relating to Revenue from Contracts with Customers

Deferred revenue represents payments received for performance obligations not yet satisfied and is presented as current or long-term in the accompanying condensed consolidated balance sheets based on the expected timing and satisfaction of the underlying goods or services. Deferred revenue was $7,699 and $3,861 as of September 30, 2026 and December 31,

10

Table of Contents

2025, respectively. During the three months ended September 30, 2026 and 2025, the Company recognized $763 and $1,159 of revenue, respectively, that was included in deferred revenue at the beginning of such periods.  During the nine months ended September 30, 2026 and 2025, the Company recognized $3,280 and $4,961 of revenue, respectively, that was included in deferred revenue at the beginning of such periods.    

As of September 30, 2026, remaining contract consideration due to unsatisfied performance obligations with an original expected duration greater than one year as of September 30, 2026 was $449, of which the Company expects to recognize $138 in one year or less, $138 in one to two years, $37 in two to three years, and $136 thereafter.

As of September 30, 2026, the Company had unsatisfied performance obligations in the amount of $598 from Assay Services contracts that the Company expects to recognize in under 12 months.

For the three and nine months ended September 30, 2026 and 2025, the Company did not incur, and therefore did not defer, any material incremental costs to obtain contracts or costs to fulfill contracts.

4.    Stockholders’ Equity

Common Stock

During the nine months ended September 30, 2026, the Company issued 29,448 shares of common stock as a result of stock option exercises, for gross proceeds of $29, issued 636,590 shares from the vesting of restricted stock units and issued 38,116 shares to employees pursuant to the MaxCyte, Inc. 2021 Employee Stock Purchase Plan (the “ESPP”) for gross proceeds of $34.

Preferred Stock

The Company’s certificate of incorporation authorizes the issuance of up to 5,000,000 shares of preferred stock, par value $0.01 per share. As of September 30, 2026 and December 31, 2025, no shares of preferred stock were issued or outstanding.

Share Repurchase

In May 2026, the Board of Directors authorized a share repurchase program under which the Company may purchase up to $10,000 of its outstanding common stock over a one-year period.  Repurchases of common stock under the program may be made from time to time in the open market, in privately negotiated transactions or by other methods, including through the use of trading plans intended to qualify under Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, or the Exchange Act, at the Company’s discretion, and in accordance with the limitations set forth in Rule 10b-18 promulgated under the Exchange Act and other applicable federal and state laws and regulations.  During the nine months ended September 30, 2026, the Company repurchased 4,260,534 shares of its common stock for an aggregate purchase amount of $5,500, and $4,500 remained available for share repurchases under the program.

Stock Incentive Plans

In May 2022, the Board of Directors adopted, and in June 2022, the Company’s stockholders approved, the MaxCyte, Inc. 2022 Equity Incentive Plan (the “2022 Plan”) to provide for the awarding of (i) incentive stock options, (ii) non-qualified stock options, (iii) stock appreciation rights, (iv) restricted stock awards, (v) restricted stock unit awards, (vi) performance awards, and (vii) other awards. Following the approval of the 2022 Plan, the Company ceased granting awards under its previously adopted MaxCyte Inc. Long-Term  Incentive Plan (the “2016 Plan”) and the MaxCyte Inc. 2021 Inducement Plan (the “2021 Inducement Plan”), although all outstanding awards continue to remain subject to the terms of the applicable plan.

Upon the effectiveness of the 2022 Plan, a total of 3,692,397 shares were initially reserved for issuance pursuant to future awards under the 2022 Plan, consisting of 1,928,000 new shares and 1,764,397 shares previously available under the 2016 Plan. If and to the extent that outstanding options under the 2016 Plan or the 2021 Inducement Plan are forfeited, the shares underlying such forfeited options will become available for issuance under the 2022 Plan. At the Company’s Annual

11

Table of Contents

Meetings of Stockholders held on June 18, 2025, June 11, 2024 and June 22, 2023, the Company’s stockholders approved to reserve an additional 2,950,000, 2,300,000, and 6,069,000 shares, respectively, for issuance pursuant to future awards under the 2022 Plan.

At September 30, 2026 and December 31, 2025, there were 6,586,000 and 8,413,000 shares, respectively, available to be issued under the 2022 Plan.

In March 2026, the Board of Directors adopted the MaxCyte, Inc. 2026 Inducement Plan (the “2026 Inducement Plan”) to provide for the awarding of (i) non-statutory stock options; (ii) stock appreciation rights; (iii) restricted stock awards; (iv) restricted stock unit awards; (v) performance awards; and (vi) other awards, in each case, only to persons eligible to receive grants of awards who satisfy the standards for inducement grants under Nasdaq Marketplace Rule 5635(c)(4) or 5635(c)(3), if applicable, and the related guidance under Nasdaq IM 5635-1. Upon adoption, 1,000,000 shares of common stock were reserved for issuance under the 2026 Inducement Plan, and an additional 650,000 shares were reserved for issuance under the 2026 Inducement Plan in September 2026.  As of September 30, 2026, there were 757,000 shares available to be issued under the 2026 Inducement Plan.

The value of an equity award is recognized as expense on a straight-line basis over the requisite service period. At September 30, 2026, total unrecognized compensation expense was $7,162, which will be recognized over an estimated weighted-average period of 2.4 years.

Stock Options

The weighted-average fair value of the stock options granted during the three months ended September 30, 2026 was estimated to be $0.83 per option share. There were no stock options granted during the three months ended September 30, 2025.  The weighted-average fair value of the stock options granted during the nine months ended September 30, 2026 and 2025 was estimated to be $0.52 and $1.72 per option share, respectively.

Restricted Stock Units (“RSUs”)

The weighted-average fair value of the RSUs granted during the three months ended September 30, 2026 and 2025 was estimated to be $1.26 and $1.97 per RSU, respectively.  The weighted-average fair value of the RSUs granted during the nine months ended September 30, 2026 and 2025 was estimated to be $0.82 and $2.94 per RSU, respectively.  

Employee Stock Purchase Plan

The ESPP allows eligible employees to purchase a number of shares of common stock, through accumulated payroll deductions, up to a maximum of 15% of the employee’s earnings during a purchase period, as defined in the ESPP, subject to certain limitations. The purchase price will be the lesser of 85% of the fair market value of a share of common stock on (i) the beginning of each purchase period and (ii) the last day of the purchase period.  Purchase periods are generally six months in length.  

The most recent purchase period began on May 19, 2026.  The weighted average fair value for the shares estimated to be purchased under the ESPP for this purchase period was $0.33 per share, which the Company will expense over the current purchase period.

12

Table of Contents

Stock-based Compensation Expense

The Company recorded stock-based compensation expense in the following expense categories on its unaudited condensed consolidated statements of operations:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

  ​ ​ ​

Three months ended September 30, 

​

Nine months ended September 30, 

​

​

2026

  ​ ​ ​

2025

​

2026

  ​ ​ ​

2025

General and administrative

​

$

647

​

$

1,205

​

$

2,092

​

$

5,297

Sales and marketing

​

 

218

​

 

282

​

 

736

​

 

1,512

Research and development

​

 

98

​

 

467

​

 

436

​

 

1,698

Total

​

$

963

​

$

1,954

​

$

3,264

​

$

8,507

​

​

5. Condensed Consolidated Balance Sheet Components

Inventory

Inventory is carried at the lower of cost or net realizable value. The following tables show the components of inventory:

​

​

​

​

​

​

​

​

​

​

  ​ ​ ​

September 30, 

  ​ ​ ​

December 31, 

​

​

​

2026

​

2025

​

Raw materials inventory

​

$

3,407

​

$

3,864

​

Finished goods inventory

​

 

3,409

​

 

3,182

​

Work in progress

​

​

564

​

​

501

​

Total inventory, net

​

$

7,380

​

$

7,547

​

​

An allowance of $1,164 and $1,531 as of September 30, 2026 and December 31, 2025, respectively, was recorded to reduce the value of inventory for items that are potentially obsolete due to expiry, product demand, or to adjust costs to their net realizable value.  

Property and Equipment

Property and equipment are stated at cost. Depreciation is computed using the straight-line method. Leasehold improvements are amortized over the shorter of the estimated lease term or useful life.

Property and equipment include capitalized costs to develop internal-use software. Applicable costs are capitalized during the development stage of the project and include direct internal costs, third-party costs and allocated interest expense as appropriate.

Property and equipment consisted of the following:

​

​

​

​

​

​

​

​

​

​

  ​ ​ ​

September 30, 

  ​ ​ ​

December 31, 

​

​

​

2026

​

2025

​

Leasehold improvements

​

$

14,787

​

$

14,787

​

Furniture and equipment

​

​

9,707

​

​

12,542

​

Internal-use software

​

 

5,500

​

 

4,635

​

Instruments

​

 

2,236

​

 

1,923

​

Construction in process

​

 

10

​

 

908

​

Accumulated depreciation and amortization

​

 

(17,898)

​

 

(17,264)

​

Property and equipment, net

​

$

14,342

​

$

17,531

​

​

During the nine months ended September 30, 2026 and 2025, the Company transferred $475 and $131, respectively, of instruments previously classified as inventory to property and equipment for instruments leased to customers. During the nine months ended September 30, 2026, the Company committed to a plan to sell certain equipment. Accordingly, the assets met the criteria to be classified as held for sale and were written down to their estimated fair value less costs to sell.  

13

Table of Contents

As of September 30, 2026, assets held for sale of $180 are included within current assets on the condensed consolidated balance sheets.

For the three months ended September 30, 2026 and 2025, the Company incurred depreciation and amortization expense of property and equipment of $883 and $1,057, respectively.  For the nine months ended September 30, 2026 and 2025, the Company incurred depreciation and amortization expense of property and equipment of $2,874 and $3,232, respectively.

Intangible Assets

Intangible assets with finite lives consist of the following:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

As of September 30, 2026

​

As of December 31, 2025

​

​

Weighted
Average
Life

​

Gross
Carrying
Amount

​

Accumulated
Amortization

​

Net
Carrying
Amount

​

Gross
Carrying
Amount

​

Accumulated
Amortization

​

Net
Carrying
Amount

Developed technology

​

15 years

​

$

621

​

$

(60)

​

$

561

​

$

471

​

$

(28)

​

$

443

Trade names

​

10 years

​

​

176

​

​

(30)

​

​

146

​

​

176

​

​

(17)

​

​

159

Customer relationships

​

7 years

​

 

56

​

 

(14)

​

 

42

​

 

56

​

 

(8)

​

 

48

Total intangible assets

​

​

​

$

853

​

$

(104)

​

$

749

​

$

703

​

$

(53)

​

$

650

​

The Company recognizes acquired intangible assets at fair value on the date of acquisition.  Intangible assets with finite lives are amortized over their useful lives using the straight-line method. The Company recorded no impairment on its finite-lived intangibles for the three and nine months ended September 30, 2026 and 2025.  

For the three months ended September 30, 2026 and 2025, the Company incurred amortization expense of intangible assets of $17 and $15, respectively. For the nine months ended September 30, 2026 and 2025, the Company incurred amortization expense of intangible assets of $51 and $36, respectively.

​

Accrued Expenses and other

Accrued expenses and other consist of the following:

​

​

​

​

​

​

​

​

​

  ​ ​ ​

September 30, 

  ​ ​ ​

December 31, 

​

​

2026

​

2025

Accrued compensation

​

$

3,790

​

$

5,628

Accrued professional fees, overhead and other

​

 

2,147

​

 

2,184

Total accrued expenses

​

$

5,937

​

$

7,812

​

​

6.    Fair Value

The Company’s condensed consolidated balance sheets include various financial instruments (primarily cash and cash equivalents, accounts receivable and accounts payable) that are carried at cost, which approximates fair value due to the short-term nature of the instruments.

The Company’s held-to-maturity investments, which consist primarily of commercial paper, U.S. Treasury securities and government agency bonds, and corporate debt instruments, are carried at amortized cost and are periodically evaluated for expected credit losses. Based on the Company’s assessment as of September 30, 2026 and December 31, 2025, no allowance for credit losses was required. The Company determined that the unrecognized holding losses were primarily due to factors other than credit deterioration, such as changes in interest rates and other market conditions.  As of September 30, 2026, the Company’s long-term investments mature between one and two years.

14

Table of Contents

The Company’s held-to-maturity investments consisted of the following amounts of amortized cost, gross unrecognized gains and losses, and estimated fair value by security type and balance sheet classification as of September 30, 2026 and December 31, 2025:

The following table summarizes the Company’s financial instruments that were measured at fair value on a non-recurring basis as of September 30, 2026:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Gross

​

Gross

​

​

​

​

​

​

​

Amortized

​

unrecognized

​

unrecognized

​

Aggregate

Description

  ​ ​ ​

Classification

  ​ ​ ​

cost

  ​ ​ ​

holding gains

  ​ ​ ​

holding losses

  ​ ​ ​

fair value

Commercial paper

 

Short-term investments

​

$

32,494

​

$

—

​

$

(59)

​

$

32,435

U.S. Treasury securities and government agency bonds

​

Short-term investments

​

​

39,245

​

​

1

​

​

(149)

​

​

39,097

Corporate debt

 

Short-term investments

​

 

16,169

​

​

—

​

​

(31)

​

 

16,138

Corporate debt

​

Long-term investments

​

​

7,193

​

​

—

​

​

(94)

​

​

7,099

U.S. Treasury securities and government agency bonds

​

Long-term investments

​

​

24,276

​

​

—

​

​

(270)

​

​

24,006

Total short-term investments and long-term investments

 

  ​

​

$

119,377

​

$

1

​

$

(603)

​

$

118,775

​

The following table summarizes the Company’s financial instruments that were measured at fair value on a non-recurring basis as of December 31, 2025:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Gross

​

Gross

​

​

​

​

​

​

​

Amortized

​

unrecognized

​

unrecognized

​

Aggregate

Description

  ​ ​ ​

Classification

  ​ ​ ​

cost

  ​ ​ ​

holding gains

  ​ ​ ​

holding losses

  ​ ​ ​

fair value

Commercial paper

 

Short-term investments

​

$

22,077

​

$

7

​

$

(4)

​

$

22,080

U.S. Treasury securities and government agency bonds

​

Short‑term investments

​

 

42,004

​

 

106

​

 

—

​

 

42,110

Corporate debt

​

Short‑term investments

​

​

18,898

​

​

14

​

​

(2)

​

​

18,910

Corporate debt

​

Long-term investments

​

​

39,558

​

​

125

​

​

—

​

​

39,683

U.S. Treasury securities and government agency bonds

​

Long-term investments

​

​

13,012

​

​

33

​

​

—

​

​

13,045

Total short-term investments and long-term investments

 

  ​

​

$

135,549

​

$

285

​

$

(6)

​

$

135,828

​

Assets and Liabilities Measured at Fair Value on a Recurring Basis

The Company had no assets or liabilities measured at fair value on a recurring basis as of September 30, 2026 and December 31, 2025.

Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis

The Company measures certain non-financial assets and liabilities, such as goodwill, intangible assets, and property and equipment, at fair value on a non-recurring basis when events or changes in circumstances indicate that their carrying amounts may not be recoverable. If the asset group is determined not to be recoverable, an impairment loss is recognized for the amount by which the carrying amount exceeds its fair value.

During the nine months ended September 30, 2026, the Company recognized an impairment charge of $630 related to certain property and equipment that management determined would no longer be used and was actively marketed for sale. The fair value of the assets was determined primarily on unobservable inputs (Level 3) based on an independent third-party estimate of anticipated recovery values for the assets. The impairment charge is included in research and development expense in the accompanying unaudited condensed consolidated statements of operations.  There were no impairment charges recognized for the three months ended September 30, 2026, and for the three and nine months ended September 30, 2025.

15

Table of Contents

The Company’s acquisition of SeQure in January 2025 included a contingent consideration agreement where the Company agreed to pay an amount up to $2,500 if SeQure achieves certain revenue targets for the years ended December 31, 2025 and December 31, 2026.  The fair value of the contingent consideration was estimated to be de minimis as of September 30, 2026 and December 31, 2025.  Contingent consideration is classified within Level 3 of the fair value hierarchy.

7.  Commitments and Contingencies

Leases

The following table represents the Company’s lease cost and supplemental lease information:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three months ended September 30, 

​

Nine months ended September 30, 

​

  ​ ​ ​

2026

  ​ ​ ​

2025

  ​ ​ ​

2026

  ​ ​ ​

2025

Operating lease cost

​

$

536

​

$

536

​

$

1,608

​

$

1,582

Short-term lease cost

​

 

—

​

 

3

​

 

8

​

 

9

Variable lease cost

​

 

361

​

 

277

​

 

1,064

​

 

870

Total lease cost

​

$

897

​

$

816

​

$

2,680

​

$

2,461

​

​

​

​

​

​

​

​

​

​

​

​

​

As of September 30,

​

As of December 31,

​

 

2026

  ​ ​ ​

2025

Operating leases

​

​

​

​

​

​

Assets

​

​

​

​

​

​

Right-of-use asset - operating leases

​

$

10,237

​

$

10,920

Liabilities

​

​

​

​

​

​

Operating lease liability, current

​

$

1,565

​

$

1,456

Operating lease liabilities, net of current portion

​

 

15,325

​

 

16,487

Total operating lease liabilities

​

$

16,890

​

$

17,943

Other information

​

​

​

​

​

​

Weighted-average remaining lease term (in years)

​

​

8.7

​

​

9.3

Weighted-average incremental borrowing rate

​

​

7.1%

​

​

7.1%

​

The following table reconciles the remaining minimum lease payments to the lease liability as of September 30, 2026:

​

​

​

​

​

​

  ​ ​ ​

Operating Leases

Remainder of 2026

​

$

662

2027

​

​

2,709

2028

​

​

2,338

2029

​

​

2,396

2030

​

​

2,456

2031

​

​

2,518

2032 and thereafter

​

​

9,786

Total undiscounted lease payments

​

​

22,865

Discount factor

​

 

(5,975)

Present value of lease liabilities

​

$

16,890

​

​

​

16

Table of Contents

8.

Segment Reporting

The Company has one reportable segment, cell engineering technology.  The cell engineering technology segment generates revenue principally from the sale of instruments, PAs and consumables, and research and clinical license fees to the Company’s customers, as well as milestone and royalty revenues as SPL customers achieve development and regulatory milestones.  The cell engineering technology used in the Company’s license revenue arrangements and instrument sales arrangements is deployed and implemented by customers in a similar manner, and brings the Company similar economic outcomes. The accounting policies of the cell engineering technology segment are the same as those described in the summary of significant accounting policies.  The Company’s chief operating decision maker (“CODM”) is the executive team which includes the Chief Executive Officer and Chief Financial Officer.  The CODM assesses performance for the cell engineering technology segment and decides how to allocate resources based on net loss and core revenues.  Core revenue includes sales of instruments, PAs and consumables, Assay and other service revenue, as well as fees from research and clinical licenses, while non-core revenue relates to SPL milestone and royalty revenue.  We recognize both core and non-core revenue in accordance with US GAAP.  The CODM uses net loss to determine whether to further resources in the cell engineering technology segment or into other parts of the entity such as for acquisitions.  The CODM also uses core revenue to assess performance of the segment and to establish Management’s compensation.  The measure of segment assets is reported on the consolidated balance sheet as total assets.  The Company does not have intra-entity sales or transfers.

The CODM is regularly provided with the following significant segment expenses which are included in the measurement of the single measure of profit (net loss):

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three months ended September 30, 

​

​

Nine Months Ended September 30, 

​

  ​ ​ ​

2026

  ​ ​ ​

2025

  ​ ​ ​

​

2026

  ​ ​ ​

2025

Core revenue

​

$

8,157

​

$

6,406

​

​

$

20,877

​

$

22,848

Non-core revenue

​

 

1,995

​

 

423

​

​

 

6,197

​

 

2,878

Total revenue

​

 

10,152

​

 

6,829

​

​

 

27,074

​

 

25,726

Cost of goods sold

​

​

1,684

​

​

1,596

​

​

​

4,928

​

​

4,612

Gross profit

​

​

8,468

​

​

5,233

​

​

​

22,146

​

​

21,114

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Expenses:

​

 

  ​

​

 

  ​

​

​

 

  ​

​

 

  ​

Research and development

​

​

2,776

​

​

5,671

​

​

​

10,548

​

​

16,612

Sales and marketing

​

 

3,996

​

 

4,925

​

​

 

10,270

​

 

15,179

General and administrative

​

 

5,906

​

 

5,788

​

​

 

17,685

​

 

18,302

Depreciation and amortization

​

​

868

​

​

1,044

​

​

​

2,837

​

​

3,185

Stock-based compensation

​

 

963

​

 

1,954

​

​

 

3,264

​

 

8,507

Total operating expenses

​

​

14,509

​

​

19,382

​

​

​

44,604

​

​

61,785

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Other income

​

​

1,279

​

​

1,733

​

​

​

4,072

​

​

5,637

​

​

 

​

​

 

  ​

​

​

 

​

​

 

  ​

Net loss

​

$

(4,762)

​

$

(12,416)

​

​

$

(18,386)

​

$

(35,034)

​

Revenue by geographic location is provided below:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three Months Ended September 30, 

​

​

Nine Months Ended September 30, 

​

  ​ ​ ​

2026

  ​ ​ ​

2025

  ​ ​ ​

​

2026

  ​ ​ ​

2025

Revenue

​

​

​

​

​

​

​

​

​

​

​

​

​

Inside the United States

​

$

7,764

​

$

3,836

​

​

$

19,010

​

$

17,184

Outside the United States

​

 

2,388

​

 

2,993

​

​

 

8,064

​

 

8,542

Total revenue

​

$

10,152

​

$

6,829

​

​

$

27,074

​

$

25,726

​

As of September 30, 2026 and December 31, 2025, substantially all of the Company’s assets were located in the United States.

​

17

Table of Contents

9.

Subsequent Events

On November 9, 2026, the Company entered into a definitive Securities Purchase Agreement to acquire Akron BioProducts LLC (“Akron Bio”) from affiliates of Arcline Investment Management for total consideration of approximately $151.8 million, consisting of $105 million in cash payable at closing, subject to customary adjustments, 20,639,733 shares of the Company’s common stock valued at approximately $26.8 million based on the Company’s stock price as of November 9, 2026, and $20.0 million in guaranteed deferred payments, consisting of $10.0 million each, payable in January 2028 and January 2029. The acquisition is expected to close before the end of 2026, subject to customary closing conditions.

​

On November 9, 2026, the Company entered into a debt financing commitment letter with MidCap Financial Trust, as administrative agent, for a credit facility of up to $75.0 million, consisting of a $55.0 million senior, secured term loan (the “Term Loan”), available in four tranches, and a $20.0 million senior secured asset-based revolving credit facility (the “Revolver”). The Company expects to draw down $20.0 million from tranche one of the Term Loan and $2.0 million from the Revolver, in each case at the closing of the acquisition. Borrowings on the Term Loan bear interest, payable monthly in arrears, at a rate per annum equal to the 30-day forward looking secured overnight financing rate (“SOFR”) plus 5.25%, subject to a SOFR floor of 2.00%. Borrowings on the Revolver are subject to availability conditions and bear interest at a rate per annum equal to SOFR plus 3.75%, subject to a SOFR floor of 2%. The Term Loan and Revolver each mature five years after the closing of the acquisition of Akron Bio, at which time all outstanding principal and accrued interest are due and payable in full.  The credit facility is subject to the execution of the definitive loan documentation and other conditions, including the closing of the acquisition.

​

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our unaudited condensed consolidated financial statements and related notes thereto included in Part I, Item 1 of this Quarterly Report on Form 10-Q, our audited consolidated financial statements and related notes for the year ended December 31, 2025 included in our Annual Report on Form 10-K filed with the SEC on March 25, 2026 (the “2025 Form 10-K”), as well as the information contained under Part II, Item 1A “Risk Factors” of this Quarterly Report on Form 10-Q, the “Risk Factors” section contained in the 2025 Form 10-K and other information provided from time to time in our other filings with the SEC.

Special Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements about us and our industry involve substantial risks, uncertainties, and assumptions, including those described elsewhere in this report. All statements other than statements of historical facts contained in this report, including statements regarding our future results of operations or financial condition, business strategy, and plans and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will” or “would” or the negative of these words or other similar terms or expressions. These forward-looking statements include, but are not limited to, statements concerning the following:

•our expected future growth and the success of our business model;

•the potential payments we may receive pursuant to our Strategic Platform Licenses (“SPLs”);

•

the size and growth potential of the markets for our products, and our ability to serve those markets, increase our market share and achieve and maintain industry leadership;

•

the market acceptance and demand for our technology and products, including in the cell therapeutics and bioprocessing application markets;

•the expected future growth of our manufacturing capabilities and sales, support and marketing capabilities;

18

Table of Contents

•our ability to expand our customer base and enter into additional SPL arrangements;

•

our ability to accurately forecast and manufacture appropriate quantities of our products to meet clinical or commercial demand;

•

our expectations regarding development of the cell therapy market, including projected growth in adoption of non-viral delivery approaches and gene editing manipulation technologies;

•our expectation that our customers will have access to capital markets to develop and commercialize their cell therapy programs;

•

our ability to maintain our FDA Master File and Master and Technical Files in other countries and expand Master and Technical Files into additional countries;

•

our research and development for any future products, including our intention to introduce new instruments and processing assemblies and move into new applications;

•

the development, regulatory approval and commercialization of competing products and our ability to compete with the companies that develop and sell such products;

•

risks associated with our ability to retain and hire senior management and key personnel;

•

regulatory developments in the United States and foreign countries;

•

our expectations regarding the period during which we qualify as an emerging growth company under the JOBS Act (as defined below);

•

our ability to develop and maintain our corporate infrastructure, including our internal controls;

•

our financial performance and capital requirements;

•the adequacy of our cash resources and availability of financing on commercially reasonable terms;

•

our expectations regarding our ability to obtain and maintain intellectual property protection for our products, as well as our ability to operate our business without infringing the intellectual property rights of others;

•general market and economic conditions that may impact investor confidence in the biopharmaceutical industry and affect the amount of capital such investors provide to our current and potential partners;

•our use of available capital resources; and

•

whether the Akron acquisition is completed, and if completed, our successful integration of Akron and realization of anticipated synergies.

You should not rely on forward-looking statements as predictions of future events. We have based the forward-looking statements contained in this Quarterly Report on Form 10-Q primarily on our current expectations and projections about future events and trends that we believe may affect our business, financial condition and operating results. The outcome of the events described in these forward-looking statements is subject to risks, uncertainties and other factors described under the caption “Risk Factors” and elsewhere in the 2025 Form 10-K. Moreover, we operate in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this report. The results,

19

Table of Contents

events and circumstances reflected in the forward-looking statements may not be achieved or occur, and actual results, events or circumstances could differ materially from those described in the forward-looking statements.

In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based on information available to us as of the date of this Quarterly Report on Form 10-Q, and while we believe that information provides a reasonable basis for these statements, that information may be limited or incomplete. Our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely on these statements.

The forward-looking statements made in this Quarterly Report on Form 10-Q relate only to events as of the date on which the statements are made. We undertake no obligation to update any forward-looking statements made in this Quarterly Report on Form 10-Q to reflect events or circumstances after the date of this Quarterly Report on Form 10-Q or to reflect new information or the occurrence of unanticipated events, except as required by law. Given these uncertainties, you should not place undue reliance on our forward-looking statements. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions or joint ventures.

You should read this Quarterly Report on Form 10-Q and the documents that we file from time to time with the SEC with the understanding that our actual future results, levels of activity, performance and events and circumstances may be materially different from what we expect.

In this Quarterly Report on Form 10-Q, unless the context requires otherwise, all references to “we,” “our,” “us,” “MaxCyte” and the “Company” refer to MaxCyte, Inc.

Trademarks

We have applied for various trademarks that we use in connection with the operation of our business. This Quarterly Report on Form 10-Q includes trademarks, service marks, and trade names owned by us or other companies. All trademarks, service marks, and trade names included in this Quarterly Report on Form 10-Q are the property of their respective owners.  Solely for convenience, the trademarks and trade names in this report may be referred to without the ® or TM symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto.

Overview

We are a global life sciences company that provides comprehensive cell engineering and gene-editing solutions to advance the discovery, development, and commercialization of next-generation cell therapies. Over more than two decades, we have developed and commercialized our proprietary platform enabling Flow Electroporation® technology, which is used by academic institutions, research centers, and biotechnology and pharmaceutical companies to facilitate complex engineering of a wide variety of cells. Electroporation is a method of transfection, or the process of deliberately introducing molecules into cells, by applying an electric field to temporarily increase the permeability of the cell membrane, enabling the intracellular delivery of molecules, such as genetic material and proteins, that would not normally be able to cross the cell membrane as easily.

Our ExPERT™ platform, based on our Flow Electroporation technology, supports the development and commercialization of next-generation cell-based medicines. The ExPERT family of products includes five instruments, which we call the DTx™, the ATx™, the STx™, the GTx™, and the VLx™, as well as a portfolio of proprietary related disposables and consumables.  Our disposables include production assemblies (“PAs”) designed for use with our instruments and our consumables include accessories supporting PAs such as electroporation buffer solution and software protocols.  Our assay services provide gene editing risk assessment services using highly sensitive assays to detect on-target and off-target gene editing effects (“Assay Services”).  We have garnered meaningful expertise in cell engineering via our internal research and development efforts as well as our customer-focused commercial approach, which includes an application scientist team.  The platform is also supported by a robust intellectual property portfolio with more than 200 granted U.S. and foreign patents and more than 100 pending patent applications worldwide.

20

Table of Contents

Our customer base includes leading commercial cell therapy and biologic developers, biotechnology and pharmaceutical companies, academic institutions, and government research organizations. Our customers have extensively validated our technology and we believe the features and performance of our platform have led to sustained customer engagement.  As of September 30, 2026, our customer base includes 28 Strategic Platform License (“SPL”) partners, a majority of the top 25 pharmaceutical companies based on 2025 global revenue, hundreds of biotechnology companies and academic research centers. Our Flow Electroporation technology is used by one of our SPL partners to engineer the first ex-vivo cell therapy approved by the FDA in December 2023.

Since our inception, we have incurred significant operating losses. Our ability to generate revenue sufficient to achieve profitability will depend on the successful further development, commercialization adoption, and market acceptance of our products. We generated revenue of $27.1 million and incurred a net loss of $18.4 million for the nine months ended September 30, 2026.  As of September 30, 2026, we had an accumulated deficit of $279.9 million. We expect to continue to incur net losses as we focus on growing commercial sales of our cell enabling solutions in both the U.S. and international markets, including expanding our sales force, scaling our manufacturing operations, and continuing research and development efforts to develop new products and further enhance our existing products.

Recent Developments

In February 2026, we announced the launch of our ExPERT DTx, a high throughput transfection platform for research and drug discovery applications.  The DTx streamlines workflows by processing up to 96 samples in a single three-minute run.  The DTx was developed for researchers whether performing gRNA or nuclease screens, antibody discovery, or evaluating novel receptor constructs.  With directly scalable, precision tuned electroporation protocols, we believe the DTx supports a clear, efficient path to downstream development and GMP-compliant manufacturing when paired with the ATx, STx and GTx.

In July 2026, we announced the expansion of our long-term partnering strategy and entered into a new enterprise-level partnership agreement with a global biopharmaceutical company. The agreement reflects our differentiated go-to-market strategy for large biopharmaceutical companies, complementing our existing SPL business model, providing access to our technology across the partner's cell therapy portfolio under a single framework supporting research, clinical development and commercial manufacturing. This approach enables us to support multiple programs within a single partnership and creates opportunities to generate revenue earlier in the development lifecycle. The agreement provides for instrument and PA purchases, annual fees and potential future milestone payments.

Acquisition of Akron Bio and Concurrent Financing

On November 9, 2026, we entered into a definitive Securities Purchase Agreement to acquire Akron Bio from affiliates of Arcline Investment Management for approximately $151.8 million, consisting of $105 million in cash at closing, subject to customary adjustments, 20,639,733 shares of our common stock valued at approximately $26.8 million based on our stock price as of November 9, 2026, and $20.0 million in guaranteed deferred payments, consisting of $10.0 million each, payable in January 2028 and January 2029.

​

The proposed acquisition of Akron Bio represents a significant step in our strategy to expand our presence across the cell therapy manufacturing workflow, diversify our revenue base, and increase our exposure to commercial-stage and late-stage clinical programs. Akron Bio is a leading supplier of GMP-grade reagents and ancillary materials used throughout the cell therapy manufacturing workflow including critical steps before and after electroporation, from cell isolation and expansion through cryopreservation. By combining Akron Bio's established portfolio of GMP-grade reagents and ancillary materials with our cell-engineering platform, we expect to significantly expand our addressable market, strengthen our financial profile, and accelerate our path to profitability.

​

The acquisition is expected to close before the end of 2026, subject to customary closing conditions, and there can be no assurance that it will be completed on that timeline or at all. If completed, we expect the acquisition to increase our revenue, operating expenses, amortization of acquired intangibles and interest expense, to result in goodwill and intangible assets, and to result in additional acquisition-related and integration costs. We have incurred, and will continue to incur, acquisition-related costs whether or not the acquisition closes.  Overall, Akron Bio is expected to generate positive

21

Table of Contents

operating cash flows, which we anticipate will contribute to our combined liquidity and support our progress toward profitability.

​

To provide additional liquidity and balance sheet flexibility, on November 9, 2026, we entered into a debt financing commitment letter with MidCap Financial Trust, as administrative agent, for a credit facility of up to $75.0 million, consisting of a $55.0 million senior, secured term loan, (the “Term Loan”) available in four tranches, and a $20.0 million senior secured asset-based revolving credit facility (the “Revolver”). We expect to initially draw down $20.0 million from tranche one of the Term Loan and $2.0 million from the Revolver, in each case at the closing of the acquisition. Borrowings on the Term Loan bear interest, payable monthly in arrears, at a rate per annum equal to the 30-day forward looking secured overnight financing rate (“SOFR”) plus 5.25%, subject to a SOFR floor of 2.00%. Borrowings on the Revolver are subject to availability conditions and bear interest at a rate per annum equal to SOFR plus 3.75%, subject to a SOFR floor of 2%. The Term Loan and Revolver each mature five years after the closing of the proposed acquisition at which time all outstanding principal and accrued interest are due and payable in full.  The credit facility is subject to the execution of definitive loan documentation and other conditions, including the closing of the acquisition, and is expected to contain affirmative and negative covenants, which may limit our operating flexibility.

​

Results of Operations

Comparison of the Three Months Ended September 30, 2026 and 2025

The following table sets forth our results of operations for the periods presented:

​

​

​

​

​

​

​

​

​

​

Three Months Ended

​

​

September 30, 

​

  ​ ​ ​

2026

  ​ ​ ​

2025

​

​

​

(in thousands)

​

​

​

​

​

​

​

Total revenue

​

$

10,152

​

$

6,829

Cost of goods sold

​

 

1,684

​

​

1,596

Gross profit

​

 

8,468

​

​

5,233

Operating expenses

​

 

  ​

​

​

  ​

Research and development

​

 

2,874

​

​

5,316

Sales and marketing

​

 

4,214

​

​

3,936

General and administrative

​

 

6,553

​

​

6,028

Restructuring expense

​

​

—

​

​

3,058

Depreciation and amortization

​

​

868

​

​

1,044

Total operating expenses

​

 

14,509

​

​

19,382

Operating loss

​

 

(6,041)

​

​

(14,149)

Other income

​

 

  ​

​

​

  ​

Interest income

​

 

1,279

​

​

1,733

Total other income

​

 

1,279

​

​

1,733

Net loss

​

$

(4,762)

​

$

(12,416)

Revenue

We generate revenue principally from the sale of instruments, single-use PAs and consumables as well as from licenses and service offerings to our customers. Our SPL agreements also include associated clinical progress milestones and sales-based payments to us, in addition to annual license payments.

In order to evaluate how our sales are trending across key markets, as well as the contribution of program economics from our SPL agreements, we separately analyze our core revenue and our performance-based milestone revenues we recognize under our SPL agreements.  Core revenue includes instrument sales, PAs and consumables, research and clinical licenses, and Assay Services, while non-core revenue relates to SPL milestone and royalty revenue.  We recognize both core and non-core revenue in accordance with US GAAP.

22

Table of Contents

The following table provides details regarding the sources of revenue for the periods presented:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three Months Ended

​

​

​

​

​

​

​

September 30,

​

Change

​

  ​ ​ ​

2026

  ​ ​ ​

2025

  ​ ​ ​

Amount

  ​ ​ ​

%

(in thousands, except percentages)

 

​

  ​

 

​

  ​

 

​

  ​

 

  ​

Core revenue:

​

​

​

​

​

​

​

​

​

​

​

Instrument revenue

​

$

2,779

​

$

1,376

​

$

1,403

 

102%

PA revenue

​

​

3,092

​

​

2,577

​

​

515

​

20%

License revenue

​

​

1,967

​

​

1,803

​

​

164

​

9%

Assay Service revenue

​

​

43

​

​

248

​

​

(205)

​

(83%)

Other service revenue

​

 

276

​

 

402

​

 

(126)

 

(31%)

Total core revenue

​

​

8,157

​

​

6,406

​

​

1,751

​

27%

SPL milestones and royalties

​

​

1,995

​

​

423

​

​

1,572

​

372%

Total revenue

​

$

10,152

​

$

6,829

​

$

3,323

 

49%

​

Total revenue for the three months ended September 30, 2026 was $10.2 million, an increase of $3.3 million, or 49%, compared to $6.8 million during the three months ended September 30, 2025.  The increase was driven by increases in core revenue and SPL milestone and royalty revenue in the amounts shown in the table above.

Total core revenue for the three months ended September 30, 2026 was $8.2 million, an increase of $1.8 million, or 27%, compared to $6.4 million for the three months ended September 30, 2025.  The overall increase in core revenue was primarily driven by increases in instrument revenue of $1.4 million, which included sales to our new enterprise pharma partner, PA revenue of $0.5 million and license revenue of $0.2 million, offset by an aggregate decrease of $0.3 million in Assay Service and other service revenue.

SPL milestone and royalty revenue continue to experience variability, although we anticipate that variability may moderate as the volume of SPL partnerships and associated milestones grows and matures.  The $1.6 million increase in SPL milestone and royalty revenues for the three months ended September 30, 2026 compared to the three months ended September 30, 2025 was primarily from a customer milestone achieved during the three months ended September 30, 2026, and an increase in royalty revenue.  

We expect total revenue to increase over time as our customers’ programs advance through the cell therapy lifecycle and our markets grow, resulting in additional instrument revenue, PA revenue and license revenue, and also as the percentage of our installed base that are under SPL license agreements increases. In addition, we believe we are well-positioned to attract new customers who may contribute to these revenues, based on the underlying growth in the cell therapy pipeline among companies in this market, the extent to which capital is available to support such companies, and in particular the switch by some cell therapy companies away from viral to non-viral approaches. We expect, however, that our revenue may fluctuate from period-to-period due to the timing of securing product sales and licenses, the inherently uncertain nature of the timing of our partners’ achievements of clinical progress, and our dependence on the program decisions of our partners.

Cost of Goods Sold and Gross Profit

Cost of goods sold primarily consists of costs for instrument and processing assembly components, contract manufacturer costs, salaries, overhead, and other direct costs related to sales recognized as revenue in the period. Cost of goods sold associated with instrument lease revenue consists of leased equipment depreciation. Gross profit is calculated as revenue less cost of goods sold. Gross profit margin is gross profit expressed as a percentage of revenue.

Our gross profit in future periods will depend on a variety of factors, including sales mix among instruments, disposables and milestones, the specific mix among types of instruments or disposables, the proportion of revenues associated with instrument leases as opposed to sales, changes in the costs to produce our various products, the launch of new products or changes in existing products, our cost structure for manufacturing including changes in production volumes, and the pricing of our products which may be impacted by market conditions.  We price our instruments at a premium given what

23

Table of Contents

we believe to be the broad benefits of our platform, and the limited availability of alternative clinically validated non-viral delivery approaches. Instrument pricing also depends upon the customer’s specific market. However, the market for non-viral delivery is highly competitive, and introduction of a Good Manufacturing Practices (“GMP”) grade platform by a competitor that delivers similar performance across a similar diversity of cell types could negatively impact our business and lead to increased price pressure that negatively impacts our gross margins.

During the three months ended September 30, 2026, gross margin was 83% compared to 77% for the three months ended September 30, 2025.  The increase in gross margin was primarily due to an increase in program milestones and royalties  during the three months ended September 30, 2026 compared to the three months ended September 30, 2025.

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

  ​ ​ ​

Three Months Ended September 30, 

  ​ ​ ​

Change

 

​

  ​ ​ ​

2026

  ​ ​ ​

2025

  ​ ​ ​

Amount

  ​ ​ ​

%

​

(in thousands, except percentages)

​

​

  ​

​

​

  ​

​

​

  ​

​

  ​

​

Cost of goods sold

​

$

1,684

​

$

1,596

​

$

88

​

6%

​

Gross profit

​

$

8,468

​

$

5,233

​

$

3,235

​

62%

​

Gross margin

​

​

83%

​

​

77%

​

​

​

​

​

​

​

Cost of goods sold increased by $0.1 million, or 6%, for the three months ended September 30, 2026 compared to the three months ended September 30, 2025. The increase was primarily driven by an increase in instrument and PA sales offset by a reduction in charges to adjust inventory down to its net realizable value.

Gross profit increased by $3.2 million, or 62%, for the three months ended September 30, 2026 compared to the three months ended September 30, 2025. The increase was primarily driven by the increases in instrument and PA sales, and by the increase in SPL milestone and royalty revenue which incur higher margins.  

We expect that our cost of goods sold will generally increase or decrease modestly as our instrument, PA and Assay Service revenue increases or decreases. We expect our gross margin to benefit from realization of milestone and royalty revenue from our SPL agreements, to the extent that such revenue grows to be a significant proportion of overall revenues, as there is no cost of goods sold associated with such revenue. However, realization and timing of these potential milestone revenues is uncertain.

Operating Expenses

Research and Development

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three Months Ended September 30, 

​

Change

 

​

  ​ ​ ​

2026

  ​ ​ ​

2025

  ​ ​ ​

Amount

  ​ ​ ​

%

​

(in thousands, except percentages)

 

​

  ​

 

​

  ​

 

​

  ​

 

  ​

​

Research and development

​

$

2,874

​

$

5,316

​

​

($2,442)

 

(46)%

​

​

Research and development expenses consist primarily of costs incurred for our research activities related to advancing our technology and development of applications for our technology, including research into specific applications and associated data development, process development, product development (e.g., development of instruments and disposables, including hardware and software engineering, and assays) and design and other costs not directly charged to inventory or cost of goods sold.

These expenses principally include employee-related costs, such as salaries, benefits, incentive compensation, stock-based compensation, and travel, as well as consultant services, facilities, and laboratory supplies, and materials. These expenses are exclusive of depreciation and amortization. We expense research and development costs as incurred in the period in which the underlying activity is undertaken.

​

​

Research and development expenses decreased by $2.4 million, or 46%, for the three months ended September 30, 2026 compared to the three months ended September 30, 2025. The decrease was primarily driven by a $1.6 million decrease in salary, personnel related expenses, and stock-based compensation, of which $1.3 million related to the workforce reduction plan executed in September 2025 and $0.3 million was attributable to less personnel-related costs being allocated

24

Table of Contents

to research and development based on our assessment of the underlying activities performed by employees supporting multiple functions, a $0.5 million decrease in lab supplies and expenses, and a $0.3 million decrease in occupancy and overhead expenses.

We believe that our continued investment in research and development is essential to our long-term competitive position. We expect to continue to incur substantial research and development expenses as we invest in research and development to support our customers, develop new uses for our existing technology and develop improved and/or new offerings to our customers and partners.  We expect these expenses to vary from period to period as a percentage of revenue.

Sales and Marketing

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three Months Ended September 30, 

​

Change

 

​

  ​ ​ ​

2026

  ​ ​ ​

2025

  ​ ​ ​

Amount

  ​ ​ ​

%

​

(in thousands, except percentages)

 

​

  ​

 

​

  ​

 

​

  ​

 

  ​

​

Sales and marketing

​

$

4,214

​

$

3,936

​

$

278

 

7%

​

​

Our sales and marketing expenses consist primarily of salaries, commissions, and other variable compensation, benefits, stock-based compensation and travel costs for employees within our commercial sales and marketing functions, as well as third-party costs associated with our marketing activities. These expenses are exclusive of depreciation and amortization.

Sales and marketing expenses increased by $0.3 million, or 7%, for the three months ended September 30, 2026 compared to the three months ended September 30, 2025 primarily due to an increase in the allocation of personnel-related costs to sales and marketing based on our assessment of the underlying activities performed by employees supporting multiple functions.

We expect our recurring sales and marketing expenses to increase in absolute dollars in future periods as we expand our commercial sales, marketing and business development teams, expand our product offerings, expand our collaboration efforts, increase our presence globally, and increase marketing activities to drive awareness and adoption of our products. We expect that in the near term, sales and marketing expenses could increase as a percentage of revenue, and thereafter vary from period to period as a percentage of revenue. The effects of such sales and marketing investments could take a few quarters to materialize into revenue growth or it may not materialize into revenue growth as expected or at all.

​

General and Administrative

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three Months Ended September 30, 

​

Change

 

​

  ​ ​ ​

2026

  ​ ​ ​

2025

  ​ ​ ​

Amount

  ​ ​ ​

%

​

(in thousands, except percentages)

 

​

  ​

 

​

  ​

 

​

  ​

 

  ​

​

General and administrative

​

$

6,553

​

$

6,028

​

$

525

 

9%

​

​

General and administrative expenses primarily consist of salaries, benefits, stock-based compensation and travel costs for employees in our executive, accounting and finance, legal, corporate development, human resources, information systems, and office administration functions as well as professional services fees, such as consulting, audit, tax and legal fees, general corporate costs, facilities and allocated overhead expenses, and public company fees associated with being a Nasdaq listed public company such as director fees, broker fees, investor relations consultants fees and insurance costs. These expenses are exclusive of depreciation and amortization.

General and administrative expenses increased by $0.5 million, or 9%, for the three months ended September 30, 2026 compared to the three months ended September 30, 2025. The increase was primarily driven by a $0.7 million increase in legal and professional services fees, mostly related to the proposed acquisition of Akron Bio, a net increase of $0.1 million in occupancy, public company, and overhead expenses, offset by a net $0.3 million decrease in salary and personnel expenses, primarily due to stock-based compensation.

​

We expect that our general and administrative expenses will increase in absolute dollars in future periods, primarily to support anticipated growth in the business.

​

25

Table of Contents

Restructuring Expense

We implemented a workforce reduction plan in September 2025 as part of our ongoing efforts to streamline operations, improve our cost structure, and align resources with strategic priorities.  For the three months ended September 30, 2025, we incurred $3.1 million in restructuring expenses.  We did not incur restructuring expenses during the three months ended September 30, 2026.

​

​

Depreciation and Amortization

Depreciation expense consists of the depreciation of property and equipment used in the business.  Depreciation related to leased instruments during the period is included in costs of goods sold in the accompanying condensed consolidated statement of operations. Amortization expense includes the amortization of intangible assets over their respective useful lives.

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three Months Ended September 30, 

​

Change

​

  ​ ​ ​

2026

  ​ ​ ​

2025

  ​ ​ ​

Amount

  ​ ​ ​

%

(in thousands, except percentages)

 

​

  ​

 

​

  ​

 

​

  ​

 

  ​

Depreciation and amortization

​

$

868

​

$

1,044

​

$

(176)

 

(17)%

​

Depreciation and amortization expense decreased by $0.2 million, or 17%, for the three months ended September 30, 2026, compared to the three months ended September 30, 2025, primarily due to a reduction in fixed asset purchases in recent years.

Interest Income

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three Months Ended September 30, 

​

Change

 

​

  ​ ​ ​

2026

  ​ ​ ​

2025

  ​ ​ ​

Amount

  ​ ​ ​

%

​

(in thousands, except percentages)

 

​

  ​

 

​

  ​

 

​

  ​

 

  ​

​

Interest income

​

$

1,279

​

$

1,733

​

$

(454)

 

(26)%

​

​

Interest income represents interest on our cash balances and investments.  Interest income decreased $0.5 million, or 26%, for the three months ended September 30, 2026 compared to the three months ended September 30, 2025.  The decrease was driven by decreases in interest rates and average cash and investment balances during the three months ended September 30, 2026.

26

Table of Contents

Comparison of the Nine Months Ended September 30, 2026 and 2025

The following table sets forth our results of operations for the periods presented:

​

​

​

​

​

​

​

​

​

  ​ ​ ​

Nine Months Ended

​

​

September 30,

​

  ​ ​ ​

2026

  ​ ​ ​

2025

​

​

(in thousands)

Total revenue

 

$

27,074

 

$

25,726

Cost of goods sold

 

​

4,928

 

​

4,612

Gross profit

 

​

22,146

 

​

21,114

Operating expenses

 

​

  ​

 

​

  ​

Research and development

 

​

10,984

 

​

17,488

Sales and marketing

 

​

11,006

 

​

15,420

General and administrative

 

​

19,777

 

​

22,634

Restructuring expense

​

​

—

​

​

3,058

Depreciation and amortization

​

​

2,837

​

​

3,185

Total operating expenses

 

​

44,604

 

​

61,785

Operating loss

 

​

(22,458)

 

​

(40,671)

Other income

 

​

  ​

 

​

  ​

Interest income

 

​

4,072

 

​

5,637

Total other income

 

​

4,072

 

​

5,637

Net loss

​

$

(18,386)

​

$

(35,034)

Revenue

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Nine Months Ended

​

​

​

​

​

​

​

September 30,

​

Change

​

  ​ ​ ​

2026

  ​ ​ ​

2025

  ​ ​ ​

Amount

  ​ ​ ​

%

(in thousands, except percentages)

 

​

  ​

 

​

  ​

 

​

  ​

 

  ​

Core revenue:

​

​

​

​

​

​

​

​

​

​

​

Instrument revenue

​

$

5,886

​

$

4,961

​

$

925

 

19%

PA revenue

​

​

7,722

​

​

9,577

​

​

(1,855)

​

(19%)

License revenue

​

​

5,885

​

​

6,953

​

​

(1,068)

​

(15%)

Assay Service revenue

​

​

476

​

​

441

​

​

35

​

8%

Other service revenue

​

 

908

​

 

916

​

 

(8)

 

(1%)

Total core revenue

​

​

20,877

​

​

22,848

​

​

(1,971)

 

(9%)

SPL milestones and royalties

​

​

6,197

​

​

2,878

​

​

3,319

​

115%

Total revenue

​

$

27,074

​

$

25,726

​

$

1,348

​

5%

​

Total revenue for the nine months ended September 30, 2026 was $27.1 million, an increase of $1.3 million, or 5%, compared to $25.7 million during the nine months ended September 30, 2025.  The increase was primarily driven by an increase in SPL milestone and royalty revenue, offset by a decrease in core revenue in the amounts shown in the table above.

​

Total core revenue for the nine months ended September 30, 2026 was $20.9 million, a decrease of $2.0 million, or 9%, compared to the nine months ended September 30, 2025.  Our overall decrease in core revenue was primarily driven by decreases in PA revenue and license revenue of $1.9 million and $1.1 million, respectively.  License revenue declined primarily due to the discontinuation of a few partner programs.  PA revenue decreased compared to the corresponding prior-year period primarily due to elevated customer purchases in the prior year due to tariff-related buying activity.  The decreases were offset by a $1.0 million increase in instrument revenue, which included sales to our new enterprise pharma partner, as well as assay service revenue during the nine months ended September 30, 2026.

27

Table of Contents

The $3.3 million increase in SPL milestone and royalty revenues for the nine months ended September 30, 2026 compared to the nine months ended September 30, 2025 is a result of our customers’ achievement of contractually specified clinical and regulatory milestones during the respective periods.  

Cost of Goods Sold and Gross Profit

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Nine Months Ended September 30, 

​

Change

 

​

  ​ ​ ​

2026

  ​ ​ ​

2025

  ​ ​ ​

Amount

  ​ ​ ​

%

​

(in thousands, except percentages)

 

​

  ​

 

​

  ​

 

​

  ​

 

  ​

​

Cost of goods sold

​

$

4,928

​

$

4,612

​

$

316

 

7%

​

Gross profit

​

$

22,146

​

$

21,114

​

$

1,032

 

5%

​

Gross margin

​

​

82%

​

​

82%

​

​

​

​

​

​

​

Cost of goods sold increased by $0.3 million, or 7%, for the nine months ended September 30, 2026 compared to the nine months ended September 30, 2025.  The increase was primarily driven by an increase in instrument sales.

​

Gross profit increased by $1.0 million, or 5%, for the nine months ended September 30, 2026 compared to the nine months ended September 30, 2025. The increase  was primarily driven by an increase in SPL milestone and royalty revenue, offset by the decreases in PA revenue and license revenue.  

Operating Expenses

Research and Development

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Nine Months Ended September 30, 

​

Change

 

​

  ​ ​ ​

2026

  ​ ​ ​

2025

  ​ ​ ​

Amount

  ​ ​ ​

%

​

(in thousands, except percentages)

 

​

  ​

 

​

  ​

 

​

  ​

 

  ​

​

Research and development

​

$

10,984

​

$

17,488

​

​

($6,504)

 

(37)%

​

​

Research and development expenses decreased by $6.5 million, or 37%, for the nine months ended September 30, 2026 compared to the nine months ended September 30, 2025.  The decrease was primarily driven by a $3.7 million decrease in salary and personnel related expenses due to the workforce reduction in September 2025, a corresponding $1.3 million decrease in stock-based compensation, a $0.8 million decrease in lab supplies and expenses, a $0.7 million decrease in engineering expense, and a $0.6 million decrease in occupancy and overhead expenses, offset by $0.6 million for an impairment charge for laboratory equipment.

​

Sales and Marketing

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Nine Months Ended September 30, 

​

Change

 

​

  ​ ​ ​

2026

  ​ ​ ​

2025

  ​ ​ ​

Amount

  ​ ​ ​

%

​

(in thousands, except percentages)

 

​

  ​

 

​

  ​

 

​

  ​

 

  ​

​

Sales and marketing

​

$

11,006

​

$

15,420

​

$

(4,414)

 

(29%)

​

​

Sales and marketing expenses decreased by $4.4 million, or 29%, for the nine months ended September 30, 2026 compared to the nine months ended September 30, 2025. The decrease was primarily driven by a $2.2 million decrease in salary and personnel related expenses due to the workforce reduction in September 2025, a $0.8 million decrease in marketing expenses, a $0.8 million decrease in stock-based compensation, and a $0.6 million decrease in professional fees, travel, and overhead expenses.

General and Administrative

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Nine Months Ended September 30, 

​

Change

 

​

  ​ ​ ​

2026

  ​ ​ ​

2025

  ​ ​ ​

Amount

  ​ ​ ​

%

​

(in thousands, except percentages)

 

​

  ​

 

​

  ​

 

​

  ​

 

  ​

​

General and administrative

​

$

19,777

​

$

22,634

​

$

(2,857)

 

(13%)

​

​

28

Table of Contents

General and administrative expenses decreased by $2.9 million, or 13%, for the nine months ended September 30, 2026 compared to the nine months ended September 30, 2025. The decrease was primarily driven by a $3.2 million decrease in stock-based compensation, a $0.9 million decrease in legal and professional fees, a $0.8 million decrease in public company fees, and a $0.4 million decrease in compensation expense and overhead expense, offset by $1.6 million charge for previously capitalized asset acquisition costs, and a $0.8 million increase in occupancy expense.

​

Restructuring Expense

We incurred $3.1 million in restructuring expense during the nine months ended September 30, 2025 due to a workforce reduction plan implemented in September 2025.  We did not incur restructuring expense during the nine months ended September 30, 2026.

Depreciation and Amortization

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Nine Months Ended September 30, 

​

Change

​

  ​ ​ ​

2026

  ​ ​ ​

2025

  ​ ​ ​

Amount

  ​ ​ ​

%

(in thousands, except percentages)

 

​

  ​

 

​

  ​

 

​

  ​

 

  ​

Depreciation and amortization

​

$

2,837

​

$

3,185

​

$

(348)

 

(11)%

​

Depreciation and amortization expense decreased by $0.3 million, or 11%, for the nine months ended September 30, 2026, compared to the nine months ended September 30, 2025 primarily due to a reduction in fixed asset purchases in recent years.

Interest Income

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Nine Months Ended September 30, 

​

Change

​

  ​ ​ ​

2026

  ​ ​ ​

2025

  ​ ​ ​

Amount

  ​ ​ ​

%

(in thousands, except percentages)

 

​

  ​

 

​

  ​

 

​

  ​

 

  ​

Interest income

​

$

4,072

​

$

5,637

​

$

(1,565)

 

(28%)

​

Interest income decreased $1.6 million, or 28%, for the nine months ended September 30, 2026 compared to the nine months ended September 30, 2025.  The decrease was driven by decreases in interest rates and average cash and investment balances during the nine months ended September 30, 2026.

Liquidity and Capital Resources

Since our inception, we have experienced losses and negative cash flows from operations. For the nine months ended September 30, 2026, we incurred a net loss of $18.4 million. As of September 30, 2026, we had an accumulated deficit of $279.9 million. To date, we have funded our operations primarily with proceeds from sales of common stock, borrowings under loan agreements and cash flows associated with sales and licenses of our products and services to customers.  

We expect to incur operating losses in the near term as we continue to invest in expanding our business through increased sales and marketing efforts, continued research and development, product development, and expansion of our product offerings. Based on our current operating plans and forecasts, and without giving effect to the proposed acquisition, we believe our existing cash, cash equivalents and investments will be sufficient to fund our operations and meet our obligations for at least 12 months from the date of issuance of these financial statements.

​

We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we expect. Our future funding requirements will depend on many factors, including:

​

​

•costs and expenses related to strategic activities and transactions;
•market acceptance of our products;
•the cost and timing of establishing additional sales, marketing and distribution capabilities;
•the cost of our research and development activities and successful development of data supporting use of our products for new applications, and timely launch of new features and products;

29

Table of Contents

•sales to existing and new customers and the progress of our SPL partners in developing their pipelines of product candidates;
•our ability to enter into additional SPL partnerships and licenses for clinical use of our platform in the future;
•changes in the amount of capital available to existing and emerging customers in our target markets;
•the effect of competing technological and market developments; and
•the level of our selling, general and administrative expenses; and
•whether the Akron Bio acquisition is completed and, if completed, our successful integration of Akron and realization of anticipated synergies.

Liquidity Considerations Related to the Proposed Acquisition

​

We expect to fund the $105.0 million closing cash consideration for our proposed acquisition of Akron Bio using existing cash, cash equivalents and investments. This may require us to sell certain held-to-maturity investments before maturity, potentially resulting in realized losses and requiring reassessment of the classification of our remaining held-to-maturity investments.

​

We have secured a debt financing commitment letter for a $75.0 million senior secured credit facility, consisting of a $55.0 million term loan and a $20.0 million revolving credit facility. We expect to initially draw down $22.0 million when the debt financing agreement is executed and the acquisition closes. The facility is intended to provide additional liquidity and balance sheet flexibility as we progress toward profitability. Additional term loan borrowings are subject to specified tranches and availability periods, while revolving credit availability depends on eligible accounts receivable and inventory balances. The facility is also expected to contain customary financial and operating covenants.

​

The proposed acquisition is expected to significantly reduce our cash and investment balances and impact our future cash requirements, including integration costs, debt service obligations and deferred consideration payments. However, Akron Bio is expected to generate positive operating cash flows, which we anticipate will contribute to our combined liquidity and support our progress toward profitability.

​

If we are unable to execute our business plan or our funding requirements exceed available cash resources, we may need additional equity or debt financing. Our ability to access the full amount of the committed credit facility is subject to borrowing restrictions and conditions, and additional financing may not be available on acceptable terms or at all. Such financing could result in dilution to existing stockholders, increased debt service obligations or additional operating restrictions. If sufficient capital is unavailable, we may need to delay product development or commercialization, reduce investments in our business or limit future strategic initiatives.  

Cash Flows

The following table summarizes our uses and sources of cash for the periods presented:

​

​

​

​

​

​

​

​

​

  ​ ​ ​

Nine Months Ended

​

​

September 30, 

(in thousands)

  ​ ​ ​

2026

  ​ ​ ​

2025

Net cash provided by (used in):

 

​

​

​

​

​

Operating activities

​

$

(18,336)

​

$

(31,721)

Investing activities

​

 

17,080

​

 

16,259

Financing activities

​

 

(5,437)

​

 

551

Net decrease in cash and cash equivalents

​

$

(6,693)

​

$

(14,911)

​

30

Table of Contents

Operating Activities

Net cash used in operating activities for the nine months ended September 30, 2026 was $18.3 million, and consisted primarily of our net loss of $18.4 million, which was offset in part by net non-cash expenses of $6.8 million.  Net non-cash expenses include stock-based compensation of $3.3 million, depreciation and amortization expenses of $2.9 million, lease right-of-use amortization of $0.7 million, an impairment on fixed assets of $0.6 million, $0.4 million in the change of excess and obsolete inventory, and an aggregate of $0.1 million in other non-cash charges offset by amortization of discounts on investments of $1.2 million. We also had net cash outflows of $6.7 million due to changes in our operating assets and liabilities.  Net changes in our operating assets and liabilities consisted primarily of an increase in accounts receivable of $8.5 million, a decrease in accounts payable and accrued expenses of $2.2 million, both of which were primarily due to timing considerations, a decrease in operating lease liabilities of $1.1 million, and an increase in inventory of $0.7 million, offset by an increase in deferred revenue of $3.8 million, and an aggregate decrease in prepaid expenses and other assets of $2.0 million.  

Net cash used in operating activities for the nine months ended September 30, 2025 was $31.7 million, and consisted primarily of our net loss of $35.0 million, which was offset in part by net non-cash expenses of $10.9 million.  Net non-cash expenses include stock-based compensation of $8.5 million, depreciation and amortization expenses of $3.3 million, and an aggregate of $1.3 million in other non-cash charges offset by amortization of discounts on investments of $2.2 million. We also had net cash outflows of $7.6 million due to changes in our operating assets and liabilities.  Net changes in our operating assets and liabilities consisted primarily of a decrease in accounts payable and accrued expenses of $3.3 million due to timing considerations, an increase in accounts receivable of $3.6 million, an increase in other assets of $0.9 million, a decrease in operating lease liabilities of $0.9 million, and a decrease in deferred revenue and other liabilities of $0.1 million, offset by a decrease in prepaid expenses and other current assets of $0.7 million and a decrease in inventory of $0.6 million.

Investing Activities

Net cash provided by investing activities during the nine months ended September 30, 2026 was $17.1 million, which was primarily attributable to maturities of investments of $72.5 million, offset by purchases of investments of $55.1 million, purchases of property and equipment of $0.2 million and $0.1 million for the acquisition of intangible assets.

Net cash provided by investing activities during the nine months ended September 30, 2025 was $16.3 million, which was primarily attributable to maturities of investments of $117.6 million, offset by purchases of investments of $98.0 million, $1.8 million for the acquisition of SeQure, net of cash acquired, and purchases of property and equipment of $1.5 million.

Financing Activities

Net cash used in financing activities during the nine  months ended September 30, 2026 was  $5.4 million, consisting of $5.5 million in repurchases of common stock offset by $0.1 million in aggregate proceeds from the exercise of stock options and proceeds from our employee stock purchase plan.

Net cash provided by financing activities during the nine months ended September 30, 2025 was $0.6 million from the exercise of stock options and employee purchases of common stock from our employee stock purchase plan.  

Contractual Obligations and Commitments

Our contractual obligations and commitments as of September 30, 2026 consisted primarily of operating lease obligations. In May 2021, we entered into the Headquarters Lease for new office, lab and warehouse/manufacturing space. The Headquarters Lease term expires on August 31, 2035. The total incremental remaining non-cancellable lease payments under the Headquarters Lease are $22.4 million through the lease term. Upon acquisition of SeQure, we assumed the SeQure Lease, which expires on December 31, 2027.  The total incremental remaining non-cancellable lease payments under the SeQure lease are $0.5 million throughout the lease term.  We expect to be able to fund our obligations under these leases, both in the short-term and in the long-term, from cash on hand, investments and operating cash flows.

31

Table of Contents

We have the obligation, if certain revenue targets are achieved, to pay an amount not to exceed $2.5 million to former holders of convertible promissory notes of SeQure for the year ended December 31, 2025 and year ending December 31, 2026.  Our estimate of the fair value of the liability for contingent consideration was de minimis as of September 30, 2026.

We had no debt obligations as of September 30, 2026 and December 31, 2025.

Purchase orders or contracts for the purchase of supplies and other goods and services are based on our current procurement or development needs and are generally fulfilled by our vendors within short time horizons.

Critical Accounting Estimates

We have prepared our condensed consolidated financial statements in accordance with U.S. GAAP. Our preparation of these condensed consolidated financial statements requires us to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, revenue, expenses and related disclosures. We evaluate our estimates and judgments on an ongoing basis. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources.

Actual results could therefore differ materially from these estimates under different assumptions or conditions.

There have been no material changes, except as described below, to our critical accounting estimates from those disclosed in our audited consolidated financial statements and the related notes and other financial information included in the 2025 Form 10-K.

Impairment of Long-Lived Assets

We consider the assessment of recoverability of our long-lived assets under ASC 360, Property, Plant, and Equipment, to be a critical accounting estimate.

​

We evaluate our long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset group may not be recoverable.  The cash-flow projections used in the recoverability assessment require management judgment in developing assumptions regarding future revenues, operating costs, customer retention and purchasing activity, and expected disposition value. Projected cash flows from customers’ future revenues represent a meaningful component of the overall cash flow projections used in the recoverability assessment.

​

The recoverability determination is sensitive to assumptions related to our customers’ ability to achieve specified contractual development milestones and commercial sales-based royalties, as the timing and achievement of those revenues directly affect projected future cash flows. Adverse changes in assumptions regarding milestone and royalty achievement could result in projected cash flows that are insufficient to recover the carrying amount of an asset group and could require the recognition of an impairment charge in future periods.

​

During the first quarter of the nine months ended September 30, 2026, certain changes in customer milestone forecast assumptions resulted in an evaluation of recoverability of our long-lived assets.  The recoverability assessment indicated the carrying value of the asset group is recoverable and accordingly, did not result in an impairment.  Separately, as described in Note 6, we recognized an impairment charge of $630,000 related to certain property and equipment that management determined would no longer be used and was actively marketed for sale. Future impairment conclusions could change if actual results differ from our assumptions or if adverse developments occur with respect to the customer’s progress toward achieving contractual milestones, customer demand, or expected disposition values.

​

Performance Stock Units

​

We have outstanding performance stock unit awards ("PSUs") granted in 2024 and 2025 that are subject to the achievement of specified performance targets through December 31, 2026 and December 31, 2027, respectively.  As of September 30,

32

Table of Contents

2026, we continued to assess achievement of the applicable performance conditions as not probable, and accordingly, no related compensation expense has been recognized for these awards.

​

Our proposed acquisition, if completed, could impact our assessment of the probability of achieving these performance targets.  If achievement becomes probable, we would recognize additional stock-based compensation expense, including a cumulative catch-up adjustment for prior service periods, which could materially impact our results of operations in future periods.

​

JOBS Act Accounting Election

We are an emerging growth company (“EGC”) under the JOBS Act. Section 107 of the JOBS Act provides that an EGC can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended for complying with new or revised accounting standards. Thus, an EGC can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to avail ourselves of the delayed adoption of new and revised accounting standards and, therefore, we will be subject to the same requirements to adopt new or revised accounting standards as private entities. We also intend to rely on other exemptions provided by the JOBS Act, including not being required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act of 2002.

We will remain an EGC until the earliest of: (i) December 31, 2026, which is the last day of the fiscal year following the fifth anniversary of our IPO in the U.S.; (ii) the last day of the first fiscal year in which our annual gross revenue is $1.235 billion or more; (iii) the date on which we have, during the previous rolling three-year period, issued more than $1 billion in non-convertible debt securities; and (iv) the last day of the fiscal year in which the market value of our common stock held by non-affiliates exceeded $700 million as of June 30 of such fiscal year.  The Company expects to cease qualifying as an EGC on December 31, 2026,  the last day of the fiscal year which is the fifth anniversary of the first sale of its registered common equity.

​

We are also a “smaller reporting company,” as defined by Rule 12b-2 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). We may continue to be a smaller reporting company if either (i) the market value of our stock held by non-affiliates is less than $250 million as of the last business day of our second fiscal quarter or (ii) our annual revenue is less than $100 million during the most recently completed fiscal year and the market value of our stock held by non-affiliates is less than $700 million as of the last business day of our second fiscal quarter. We expect to remain a smaller reporting company at the time we cease to be an emerging growth company, and expect to continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies.

Recent Accounting Pronouncements

A description of recently issued accounting pronouncements that may potentially impact our financial position, results of operations or cash flows is disclosed in Note 2 to our unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Interest Rate Risk

We are exposed to market risk for changes in interest rates related primarily to balances of our financial instruments including cash and cash equivalents and investments. The primary objective of our investment approach is to preserve principal and provide liquidity. As a result, a 10% change in the level of market interest rates would not be expected to have a material effect on our business, financial condition or results of operations.

As of September 30, 2026, we had no indebtedness and therefore were not exposed to interest rate risk from increases in interest rates. If the Akron acquisition closes, we expect to borrow under our new credit facility, and these borrowings will bear interest at variable rates based on SOFR (subject to a floor), and we will be exposed to interest rate risk on those

33

Table of Contents

borrowings. A 100 basis point increase in SOFR would increase annual interest expense by approximately $220,000 based on $22,000,000 outstanding.

Foreign Currency Risk

We are exposed to financial risks as a result of exchange rate fluctuations between the U.S. Dollar and certain foreign currencies and the volatility of these rates. In the normal course of business, we earn revenue primarily denominated in U.S. Dollars as well as in Euros and British Pounds. We incur expenses primarily in U.S. Dollars as well as in Euros, British Pounds, and other currencies. Our reporting currency is the U.S. Dollar. We hold our cash primarily in U.S. Dollars as well as in Euros and British Pounds. We do not expect that foreign currency gains or losses will have a material effect on our financial position or results of operations in the foreseeable future. We have not entered into any hedging arrangements with respect to foreign currency risk. As our international operations grow, we will continue to assess our approach to managing risks relating to fluctuations in currency exchange rates.

Inflation Risk

During the last two years, inflation and changing prices have not had a material effect on our business. We are unable to predict whether inflation or changing prices will materially affect our business in the foreseeable future.

​

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

We carried out an evaluation, under the supervision and with the participation of management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our “disclosure controls and procedures” as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on our evaluation, our Chief Executive Officer and Chief Financial Officer concluded that the design and operation of these disclosure controls and procedures were effective as of September 30, 2026 at the reasonable assurance level.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting during the three months ended September 30, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

​

34

Table of Contents

​

PART II. OTHER INFORMATION

Item 1. Legal Proceedings.

From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. We are not currently a party to any material legal proceedings, and we are not aware of any pending or threatened legal proceeding against us that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations.

​

Item 1A. Risk Factors.

Our business is subject to risks and events that, if they occur, could adversely affect our financial condition and results of operations and the trading price of our securities. In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the factors described in Part I, Item 1A. “Risk Factors” and elsewhere in the 2025 Form 10-K. Except as set forth below, there have been no material changes to the risk factors set forth in that report.

​

Risks Related to the Proposed Akron Acquisition and Our New Indebtedness

The Akron acquisition may not be completed on the expected timeline or at all, and a failure to complete it could adversely affect our business and the market price of our common stock.

Completion of the Akron acquisition is subject to customary closing conditions, some of which are outside our control, and the Securities Purchase Agreement may be terminated in certain circumstances. We cannot assure that the conditions will be satisfied or that the acquisition will close on the expected timeline or at all. If the acquisition is not completed, we will have incurred significant legal, advisory, financing and other costs, many of which are payable regardless of whether the acquisition closes, without realizing any of its anticipated benefits; our management’s attention will have been diverted from our existing business; and the market price of our common stock, which may reflect an assumption that the acquisition will be completed, could decline. In addition, the availability of our new credit facility is expected to depend on the closing of the acquisition, and because the number of shares we will issue as consideration is fixed, the value of the share consideration at closing will fluctuate with the price of our common stock.

We have incurred, and expect to continue to incur, significant costs in connection with the Akron acquisition, which, if completed, will reduce our cash resources and increase our fixed obligations.

If the Akron acquisition closes, we will pay $105.0 million in cash and issue 20,639,733 million shares of our common stock, which will dilute our existing stockholders and, if sold into the market by the recipient, could depress the market price of our common stock, and we will be obligated to pay $20.0 million in guaranteed deferred payments in January 2028 and January 2029 regardless of Akron’s performance. We have also incurred, and expect to continue to incur, substantial advisory, legal, financing and other transaction costs, many of which are payable whether or not the acquisition closes, and, if it closes, we expect to incur costs to integrate Akron, including for systems, facilities, personnel and quality and regulatory compliance. Many of these costs are payable whether or not the anticipated benefits of the acquisition are realized, and they may exceed our estimates. In addition, if the acquisition closes, purchase accounting will require us to record significant goodwill and intangible assets, and the related amortization will reduce our reported results. Using our cash for the acquisition will reduce the funds available for our existing business and other opportunities and may require us to seek additional financing sooner than anticipated, which may not be available on acceptable terms or at all.

We may not realize the anticipated benefits of the Akron acquisition, and integrating Akron may be more difficult, costly or time-consuming than expected.

If the Akron acquisition is completed, its success will depend on our ability to integrate Akron’s operations, personnel, manufacturing, quality and information systems with ours and to achieve the anticipated benefits, including cross-selling opportunities, an expanded addressable market and improved profitability. Akron’s business, which supplies reagents and

35

Table of Contents

ancillary materials, differs from our historical focus on electroporation instruments and related services, and we have limited experience operating a business of this type. We may have difficulty retaining Akron’s customers, employees and suppliers; Akron’s customers may reduce or delay purchases as a result of the acquisition or changes in their own programs; and because few of Akron’s customers are currently our customers, cross-selling may not occur as expected. Akron’s products are manufactured under cGMP and other regulatory requirements, and any quality or compliance failure could affect Akron’s customers’ regulatory filings and our reputation. Akron is privately held, and we may need to devote significant resources to bring its financial reporting and internal controls into compliance with the requirements applicable to us as a public company. We may also be subject to unknown or contingent liabilities of Akron for which indemnification is unavailable or insufficient, may be required to record impairment charges on goodwill or intangible assets, and may find that management’s attention is diverted from our existing business. Akron’s historical results, including its revenue and profitability, may not be indicative of its future performance as part of our company. If we do not realize the anticipated benefits in the expected time frame or at all, our business, financial condition, results of operations and stock price could be adversely affected.

Our new indebtedness, and the covenants in our credit facility, could restrict our operations and adversely affect our financial condition.

We currently have no indebtedness. In connection with the Akron acquisition, we expect to enter into a credit facility with MidCap Financial Trust, as administrative agent, providing for up to $55.0 million of term loans and a $20.0 million revolving line of credit, under which we expect to borrow $20.0 million and $2.0 million, respectively, at closing. The facility is expected to be secured by a first-priority lien on substantially all of our assets, including our intellectual property, and a pledge of the equity of our subsidiaries. Following the closing, we will be required to dedicate a portion of our cash flow to debt service; borrowings will bear interest at variable rates based on SOFR (subject to a floor), so increases in interest rates will increase our costs; and the term loan principal will be payable in a single payment at maturity, approximately five years after closing, when we may not have sufficient funds to repay or refinance it. We may also owe fees, including a final payment fee and, if we prepay or terminate the facility early, prepayment fees. We may not be able to access the full amount of the facility: additional term loan tranches are expected to be available only if specified conditions are met or in the lender’s discretion, and availability under the revolver is expected to be limited by a borrowing base tied to eligible receivables and inventory. The credit agreement is expected to contain customary affirmative and negative covenants that limit our ability to, among other things, incur additional indebtedness or liens, make acquisitions and investments, dispose of assets, pay dividends and repurchase our stock; the final terms remain subject to definitive documentation. Our ability to comply with these covenants will depend on our operating performance, which may be affected by events beyond our control, including the risks described above. A breach could result in an event of default, which could allow the lenders to accelerate our indebtedness, terminate their commitments and foreclose on our collateral, any of which could materially harm our business.

​

​

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

(a) Sale of Unregistered Securities

None.

(b) Use of Proceeds

Not applicable.

​

36

Table of Contents

(c) Purchases of Equity Securities

A summary of our common stock repurchases (in thousands, except average price per share and number of shares) for the three months ended September 30, 2026 is as follows:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

(c) Total number of shares

​

Approximate Dollar Value

​

​

​

​

​

​

purchased as part of

​

of Shares That May

​

​

(a) Total number of

​

(b) Average Price

​

publicly announced

​

yet to be Purchased

Description

  ​ ​ ​

Shares Repurchased(i)

  ​ ​ ​

Paid Per Share (ii)

  ​ ​ ​

plans or programs (i)

  ​ ​ ​

Under the Plans

July 1-31 2026

​

​

2,947,468

​

$

1.36

 

 

2,947,468

​

$

4,500

​

​

​

​

​

​

​

​

​

​

​

​

​

August 1-31 2026

 

 

—

​

​

—

 

 

—

​

$

4,500

​

​

​

​

​

​

​

​

​

​

​

​

​

September 1-30 2026

​

​

—

​

​

—

 

 

—

​

$

4,500

Total

 

​

2,947,468

​

$

1.36

 

​

2,947,468

​

$

4,500

(i)All shares were repurchased pursuant to a $10 million repurchase authorized by our Board and publicly announced on May 12, 2026. Shares repurchased under this plan may be in open market transactions, privately negotiated transactions, or in accordance with an adopted 10b5-1 plan. Of the 2,947,468 shares purchased during the three months ended September 30, 2026, 2,864,911 were purchased pursuant to an adopted 10b5-1 plan. The remaining 82,557 shares were purchased in open market transactions. The program expires May 5, 2027.
(ii)Average price paid per share in the period includes commission.

​

Item 3. Defaults Upon Senior Securities.

None.

​

Item 4. Mine Safety Disclosures.

Not applicable.

​

Item 5. Other Information.

None

37

Table of Contents

Item 6. Exhibits.

The following exhibits are filed with this Quarterly Report, or incorporated by reference into, on Form 10-Q:

Incorporated by Reference

Exhibit

Number

Description

Form

File No.

Exhibit

Filing Date

31.1

Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2

Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1*

Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2*

Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS

​

Inline XBRL Instance Document.

​

​

​

​

​

​

​

​

101.SCH

​

Inline XBRL Taxonomy Extension Schema Document

​

​

​

​

​

​

​

​

101.CAL

​

Inline XBRL Taxonomy Extension Calculation Linkbase Document

​

​

​

​

​

​

​

​

101.DEF

​

Inline XBRL Taxonomy Extension Definition Linkbase Document

​

​

​

​

​

​

​

​

101.LAB

​

Inline XBRL Taxonomy Extension Label Linkbase Document

​

​

​

​

​

​

​

​

101.PRE

​

Inline XBRL Taxonomy Extension Presentation Linkbase Document

​

​

​

​

​

​

​

​

104

​

Cover Page Interactive Data File (formatted as inline XBRL with applicable Taxonomy Extension information contained in Exhibits 101.SCH, 101.CAL, 101.DEF, 101.LAB and 101.PRE).

​

​

​

​

​

​

​

​

​

​

*

This exhibit shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act of 1934, whether made before or after the date hereof and irrespective of any general incorporation language in such filing.

​

38

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

​

​

MaxCyte, Inc.

​

​

Date: November 10, 2026

By:

/s/ Maher Masoud

​

Name:

Maher Masoud

​

Title:

President and Chief Executive Officer (Principal Executive Officer)

​

​

​

​

Date: November 10, 2026

By:

/s/ Parmeet Ahuja

​

Name:

Parmeet Ahuja

​

Title:

Chief Financial Officer (Principal Financial Officer)

​

39

Keep reading